Acute kidney injury in severe sepsis and septic shock by Poukkanen, Meri
 
 
Department of Anaesthesiology and Intensive Care Medicine 
Helsinki University Central Hospital 
University of Helsinki 
Helsinki, Finland 
 
 
 
 
 
 
ACUTE KIDNEY INJURY IN 
SEVERE SEPSIS AND SEPTIC SHOCK  
 
Meri Poukkanen 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented with the permission of the Medical Faculty of  
the University of Helsinki, for public examination in  
Haartman Institute Helsinki, Lecture room 2, Haartmaninkatu 3,  
on 16th January 2015, at 12 noon. 
 
HELSINKI 2015 
  
 SUPERVISORS 
 
Docent Ville Pettilä 
Department of Anaesthesiology and Intensive Care Medicine 
Helsinki University Central Hospital 
Helsinki, Finland 
 
Sari Karlsson, MD, PhD 
Department of Intensive Care Medicine 
Tampere University Central Hospital 
Tampere, Finland 
 
 
REVIEWERS 
 
Professor Arvi Yli-Hankala 
University of Tampere  
Tampere, Finland 
 
Docent Asko Järvinen 
Division of Infectious Diseases  
Department of Medicine, Helsinki University Central Hospital 
Helsinki, Finland 
 
 
OFFICIAL OPPONENT 
 
Professor Konrad Reinhart 
Director of Department for Anaesthesiology and Intensive Care  
Jena University Hospital 
Jena, Germany 
 
 
 
 
 
ISBN 978-951-51-0111-2 (pbk.) 
ISBN 978-951-51-0112-9 (PDF) 
Https://ethesis. helsinki.fi 
Unigrafia Oy 
Helsinki 2015 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Tuomo and Veikka  
 
 LIST OF CONTENTS 
LIST OF ORIGINAL PUBLICATIONS ................................................................... 7 
LIST OF ABBREVIATIONS .................................................................................. 8 
ABSTRACT ........................................................................................................... 10 
1. INTRODUCTION .............................................................................................. 12 
2.REVIEW OF THE LITERATURE ..................................................................... 14 
2.1 Definitions .................................................................................................. 14 
2.1.1 Severe sepsis and septic shock ............................................................ 14 
2.1.2 Acute kidney injury (AKI) ................................................................... 15 
2.2 Evaluation of renal function ...................................................................... 18 
2.2.1. Glomerular filtration rate (GFR) ....................................................... 18 
2.2.2 Estimations of GFR ........................................................................... 20 
2.3. Incidence of septic AKI and severe sepsis ................................................22 
2.4 Pathophysiology of septic AKI ...................................................................24 
2.4.1 Alterations in renal blood flow ...........................................................24 
2.4.2 Microcirculatory alterations ...............................................................26 
2.4.3 Inflammation ...................................................................................... 27 
2.4.4 Apoptosis ............................................................................................ 27 
2.4.5 Mechanical ventilation ...................................................................... 28 
2.5 Biomarkers of septic AKI .......................................................................... 28 
2.6 Risk factors of septic AKI ........................................................................... 29 
2.7 Treatment of septic AKI ............................................................................ 30 
2.7.1 Antimicrobial treatment of infection ................................................. 30 
2.7.2 Treatment of haemodynamic dysfunction ......................................... 31 
2.7.3 Renal replacement therapy (RRT) ..................................................... 34 
2.8 Outcome ..................................................................................................... 35 
2.8.1 Short- and long-term mortality .......................................................... 35 
2.9 Predictive models ....................................................................................... 37 
2.9.1 General ICU models ............................................................................ 37 
2.9.2 AKI-specific predictive models .......................................................... 38 
2.9.3 Predictive ability of general ICU-scores and AKI criteria ................ 40 
3. AIMS OF THE STUDY ..................................................................................... 42 
4. PATIENTS AND METHODS............................................................................ 43 
4.1 Patients ....................................................................................................... 43 
4.2 Study designs and objectives ..................................................................... 46 
4.3 Data collection ...........................................................................................48 
4.4 Definitions .................................................................................................. 49 
4.5 Outcome measures ..................................................................................... 51 
4.6 Statistical methods ..................................................................................... 52 
4.7 Ethical aspects ............................................................................................ 54 
5. RESULTS .......................................................................................................... 55 
 5.1 Incidence of severe sepsis associated AKI (I) ............................................ 55 
5.2. Association with early haemodynamics and progression of septic AKI (II) 
  ........................................................................................................................ 59 
5.3 Variation in use of RRT in septic shock associated AKI (III) ................... 60 
5.4 Outcome (I-IV) ........................................................................................... 61 
5.5 Predictive models for one-year mortality in patients with AKI .........62 
6. DISCUSSION ................................................................................................... 64 
6.1. Incidence of severe sepsis and septic shock associated AKI ................... 64 
6.2 Mean arterial pressure and progression of AKI ........................................ 65 
6.3 RRT in severe sepsis and septic shock ...................................................... 66 
6.4 Outcome of severe sepsis associated AKI ................................................. 68 
6.5 Predictive model for one-year mortality in patients with AKI ................. 68 
6.6 Strengths and limitations of the studies ....................................................70 
6.7 Clinical implications and future perspectives ........................................... 72 
7. CONCLUSIONS ................................................................................................ 75 
8. ACKNOWLEDGEMENTS ................................................................................ 76 
REFERENCES ...................................................................................................... 78
(IV)
7 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original publications referred to in text 
by their Roman numerals (I-IV). Articles have been reprinted with the kind 
permission of their copyright holder. 
 
 
I  Poukkanen M, Vaara ST, Pettilä V, Kaukonen KM, Korhonen 
AM, Hovilehto S, Inkinen O, Laru-Sompa R, Kaminski T, 
Reinikainen M, Lund V, Karlsson S; the FINNAKI study group. 
Acute kidney injury in patients with severe sepsis in Finnish 
Intensive Care units. Acta Anaesthesiol Scand 2013, 57:863-872 
 
II  Poukkanen M*, Wilkman E*, Vaara ST, Pettilä V, Kaukonen KM, 
Korhonen AM, Uusaro A, Hovilehto S, Inkinen O, Laru-Sompa 
R, Hautamäki R, Kuitunen A, Karlsson S; the FINNAKI Study 
Group. Hemodynamic variables and progression of acute kidney 
injury in critically ill patients with severe sepsis: data from the 
prospective observational FINNAKI study. Crit Care. 2013; 
17(6):R295. 
* equal contribution 
 
III  Poukkanen M, Koskenkari J, Vaara ST, Pettilä V, Karlsson S, 
Korhonen AM, Laurila JJ, Kaukonen KM, Lund V, Ala-Kokko TI; 
the FINNAKI Study Group. Variation in the use of renal 
replacement therapy in patients with septic shock: a substudy of 
the prospective multicenter observational FINNAKI study. Crit 
Care. 2014;2014:18(1):R26 
 
IV Poukkanen M, Vaara ST, Reinikainen M, Selander T, Nisula S, 
Karlsson S, Parviainen I, Koskenkari J, Pettilä V; The FINNAKI 
Study Group. Predicting one-year mortality of critically ill 
patients with early acute kidney injury. Critical CareI 
(Submitted) 
 
 8 
LIST OF ABBREVIATIONS  
ACCP/SCCM American College of Chest Physicians/Society of 
Critical Care  
ADQI  Acute Dialysis Quality Initiative  
AKI  Acute kidney injury 
AKIN  Acute Kidney Injury Network  
APACHE   Acute Physiology and Chronic Health Evaluation  
ATN  Acute tubular necrosis 
AUC Area under the receiver operating characteristic 
curve 
BUN  Blood urea nitrogen 
CKD-EPI  Chronic Kidney Disease Epidemiology Collaboration 
CO  Cardiac output 
Cp  Concentration of a substance in plasma  
Cr  Creatinine  
CrCl  Creatinine clearance 
CRF  Case report form 
CRRT  Continuous renal replacement therapy 
Cu   Concentration of a substance in urine  
CVP   Central venous pressure 
DAMP  Damage-associated molecular pattern 
DIC  Disseminated intravascular coagulation 
FICC  Finnish Intensive Care Quality Consortium 
GFR  Glomerular filtration rate 
GoF  Hosmer-Lemeshow goodness-of fit  
HES  Hydroxyethyl starches 
HVHF  High volume hemofiltration 
ICU  Intensive care unit 
IHD  Intermittent hemodialysis 
IL-6/18  Interleukin-6/18 
iNO   Inducible nitric oxide 
KDIGO  Kidney Disease: Improving Global Outcome 
KIM  Human kidney injury molecule 
L-FABP  Liver fatty acid-binding protein 
MAP  Mean arterial pressure 
MDRD  Modification of Diet in Renal Disease Medicine 
MRI  Magnetic resonance imaging 
NGAL  Neutorophil gelatinase-associated lipocalin 
NO  Nitric oxide 
∆OF Difference in the number of failed organs between 
on day 3 versus day 1 in the ICU 
OR   Odds ratio 
9 
PAMP  Pathogen-associated molecular pattern 
Qu  Urine flow rate  
RIFLE  Risk, Injury, Failure, Loss, End-Stage 
ROC  Receiver operating characteristic 
RRT  Renal replacement therapy 
SAPS  Simplified Acute Physiology Score  
SIRS  Systemic inflammatory response syndrome  
SMR   Standardized mortality ratio 
SOFA  Sequential Organ Failure Assessment  
SSC  Severe Sepsis Campaign 
svO2  Mixed central venous saturation  
TLR  Toll-like receptor 
TNF-?  Tumor necrosis factor ? 
 10 
ABSTRACT 
Background: Severe sepsis and septic shock are the main causes of acute 
kidney injury (AKI) in the intensive care unit (ICU). The care of these 
patients includes restoration of haemodynamics by fluid resuscitation and 
vasoactive treatment. Development of septic AKI has been shown to associate 
with lower mean arterial pressure (MAP) levels. The treatment of AKI is 
supportive. No generally accepted guidelines for indication or optimal timing 
for initiation of renal replacement therapy (RRT) exist. Apart from life-
threatening indications, the initiation of RRT is mainly based on clinical 
judgment. The short- and long- term mortality rates of these patients are 
high. The long-term mortality of hospital survivors with AKI remains 
increased for several years after critical illness. The objectives of this study 
were to assess the incidence and 90-day mortality of ICU-treated patients 
with severe sepsis associated AKI (I), to evaluate the impact of early 
haemodynamics on development of AKI (II), to assess the differences in 
proportion of administration of RRT in patients with septic shock (III), and 
to develop predictive models for one-year mortality among all ICU-treated 
patients with AKI (IV). AKI was defined and staged by Kidney Disease: 
Improving Global Outcomes (KDIGO) criteria. 
 
Patients: All patients and analyses were performed using data from the 
FINNAKI study, which was a prospective, observational study conducted in 
17 Finnish ICUs between September 1, 2011 and February 1, 2012. Study I 
comprised 918 adult patients, who fulfilled the criteria for severe sepsis 24 
hours preceding ICU admission or within the first five days in the ICU. Study 
II included 423 patients with severe sepsis diagnosed within 24 hours of ICU 
admission. Study III comprised patients with septic shock (N=726). In study 
III the participating ICUs were divided into high-RRT ICUs and low-RRT 
ICUs by the proportion of patients with septic shock treated with RRT. In 
study IV, 774 patients with early AKI (diagnosed within 24 hours of ICU 
admission) were analysed.  
 
Main results: Of the 918 patients with severe sepsis, 488 had AKI (53%, 
95% confidence interval, CI 49.9-56.5%). The population-based incidence of 
ICU-treated severe sepsis associated AKI was 0.32 (95%CI 0.30-0.34)/ 1000 
adults/year. The 90-day mortality rate of the patients with severe sepsis 
associated AKI was 186/488 (38.1%, 95% CI 33.7-42.5%) compared to 
106/430 (24.7%, 95%CI 20.5-28.8) in patients with severe sepsis without 
AKI, (P<0.001). Patients with severe sepsis associated AKI were older, had 
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more comorbidities, and daily chronic medications than those without AKI. 
Patients with AKI were more severely ill in terms of higher maximum SOFA 
(Sequential Organ Failure Assessment) score (P<0.001), had higher lactate 
concentrations (P<0.001), and they received more often mechanical 
ventilation (P<0.001) and vasoactive treatment (P=0.004) than patients 
without AKI. The most severe AKI, KDIGO stage 3, was independently 
associated with 90-day mortality (OR 2.6, 95%CI 1.8-3.7). Patients with 
severe sepsis and development of AKI had lower time-adjusted MAP 
(95%CI), 74.4mmHg (68.3-80.8), than those patients without progression of 
AKI, 78.6 mmHg (72.9-85.4 mmHg, P<0.001).  
The proportion of RRT-treated patients in patients with septic shock ranged 
from 3% to 35 % across Finnish ICUs. This variation between high- and low-
RRT ICUs was explained by differences in case-mix and in severity of organ 
dysfunction. Indications for and modality of RRT did not differ between ICU 
groups. The group of ICU (high-RRT or low-RRT ICU) did not increase the 
risk of fatal outcome in these patients. 
The one-year mortality among patients with AKI was 39.8% (95%CI 36.3-
43.3). A predictive model for one-year mortality for patients with early AKI 
based on data available by the third day in the ICU (D3 model) performed 
fairly well with an AUC -value (95%CI) of 0.80 (0.753-0.846) and a 
bootstrapped AUC-value (95%CI) of 0.79 (0.77-0.80). Advanced age, 
mechanical ventilation on D3, number of co-morbidities, higher modified 
SAPS II score, the highest bilirubin value by D3, and the lowest base excess 
value on D3 were predictors of one-year mortality on D3 model. The severity 
of AKI, or the presence of severe sepsis, did not remain as predictors for one-
year mortality. 
 
Conclusions: Over half of the patients with severe sepsis had AKI. These 
patients had a worse outcome, but only AKI KDIGO stage 3 was 
independently associated with 90-day mortality. Avoidance of time-adjusted 
MAP below 73mmHg may be beneficial for prevention of the progression of 
AKI in patients with severe sepsis. Despite 10-fold variation in proportion of 
RRT in patients with septic shock, the 90-day mortality of these patients was 
similar between high-RRT ICUs and low-RRT ICUs. The D3 model might be 
clinically useful in identifying patients with high risk for long-term mortality 
but it requires further validation. 
 12 
1. INTRODUCTION 
Severe sepsis and acute kidney injury (AKI) are both common syndromes 
that are encountered in the intensive care unit (ICU). The proportion of 
patients presenting severe sepsis upon admission to the ICU has been 
reported to be approximately 9% to 12%.1-5 An increasing trend in the 
presence of severe sepsis in ICU-treated patients has been observed.1,5 In 
France, the proportion of patients with severe sepsis among all ICU 
admissions increased from 8.4% in 1993 to 14.6% in 20011; and in Australia 
and New Zealand an increase from 7.2% in 2000, to 11.1% in 2012 was seen.5 
A similar change has also been seen in the U.S. for hospitalized patients with 
severe sepsis.6,7  
 
The incidence of AKI in patients with severe sepsis treated in the ICU ranges 
from 23% up to 67%.8-23 The short-term mortality in patients with severe 
sepsis associated AKI has ranged from 16% up to 70%. 8,10,11,16,18,20-22,24-28 The 
treatment of severe sepsis associated AKI includes treatment of severe sepsis 
according to the Severe Sepsis Campaign (SSC) guidelines29 and supportive 
treatment of AKI. The cornerstones of treatment of severe sepsis are 
restoration of haemodynamics with appropriate fluid resuscitation and 
vasoactive treatment when needed.29 Recent studies have shown increase in 
mortality and in need for renal replacement therapy with administration of 
hydroxyethyl starches (HES).30-34 According to the updated SSC29 and 
KDIGO35 (Kidney Disease: Improving Global Outcome) guidelines starches 
should not be used in severe sepsis.29,35 Norepinephrine is advocated to be 
administrated to restore the blood pressure in severe sepsis associated AKI 
when resuscitation with fluids is inadequate to normalize blood pressure.35 
When infused directly into a renal artery, norepinephrine has induced renal 
vasoconstriction36,37 and an increased renal vascular resistance has been 
observed with high doses (up to 1.6μg/kg/min) of intravenous 
norepinephrine.38 However, with lower doses of norepinephrine (0.2-
0.4μg/kg/min) renal vascular resistance has decreased and renal blood flow 
has not changed or has increased.39-42  
 
The historical paradigm of reduced renal blood flow and acute tubular 
necrosis (ATN)43 has been strongly challenged by advanced measurements of 
renal blood flow.42,44-51 In addition, histopathological findings of renal 
tubular necrosis have not provided evidence of ATN.52,53 A systematic review 
of the histopathology of septic AKI, including six human and 14 experimental 
studies, concluded that the current human and experimental data do not 
support the theory of ATN as the mechanism of septic AKI.54 Hypotensive 
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episodes with mean arterial pressure (MAP) below 65-82mmHg have been 
shown to increase the risk of AKI and the related administration of RRT in 
patients with severe sepsis.12,55-57. The sufficient MAP level remains to be 
clarified and may vary in different patient groups.  
 
No specific treatment for severe sepsis associated AKI exists and, thus, the 
treatment of AKI is supportive. Renal replacement therapy (RRT) is used in 
9% to 70 % of patients with severe sepsis associated AKI. 8,11,16,17,20,24,58,59 Part 
of the large variation is explained by differences in study population, but also 
by lack of guidelines regarding indications and proper timing of RRT. The 
initiation of RRT is mainly based on local protocols and on the clinical 
judgment of the attending physician. For haemodynamically unstable 
patients, such as patients with septic shock, continuous RRT is 
recommended.35,60 The optimal RRT practice for patients with severe sepsis 
associated AKI may be unique due to the distinct pathophysiology of septic 
AKI.61 However, according to current data, the high volume hemofiltration 
(HVHF) that aims to purify the blood of inflammatory mediators has not 
shown any beneficial effect (reduced mortality or improvement of organ 
dysfunction) in septic AKI, and therefore it is not recommended as a 
treatment for septic AKI.62,63  
 
Prognostic models for hospital mortality have been used for ICU-treated 
patients since the 1980s.64-71 Considering the high costs and resource use of 
ICU-treated patients with AKI, an instrument to estimate the possibility of 
futile intensive care treatment is crucial. Although the long-term mortality of 
survivors of ICU-treated AKI patients has been found to be increased for up 
to 10 years,25,72-79 no prediction model for long-term mortality exists.  Most of 
the present AKI-specific models provide estimates for short-term 
mortality.80-83. In addition, these models have performed poorly when 
externally validated.84,85 A model developed by using data on RRT-treated 
patients may not be applicable to patients with less severe AKI without 
customization and validation.86 Moreover, none of the AKI-specific models 
have used current definitions RIFLE (Risk, Injury, Failure, Loss and End-
stage renal disease), AKIN (Acute Kidney Injury Network), or KDIGO to 
define and stage AKI. Recent improvements in survival of patients with 
severe sepsis5,87 and in patients with AKI26 may have improved the outcome 
of patients with AKI. Therefore, a novel AKI-specific predictive model for 
long-term mortality, defining AKI by current classification, is needed.  
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2.REVIEW OF THE LITERATURE 
2.1 Definitions 
2.1.1 Severe sepsis and septic shock  
 
Sepsis is a host’s response to proven or suspected infection with at least two 
systemic inflammatory response syndrome (SIRS) criteria.88 The SIRS 
criteria encompass alterations in body temperature, heart rate, respiratory 
rate, and leukocytes. Severe sepsis is defined as sepsis with organ 
dysfunction. Septic shock is severe sepsis with hypotension or hypoperfusion, 
which is not reversed with adequate fluid resuscitation. Patients treated with 
vasoactive therapies may not be hypotensive at the time of perfusion 
derangements, yet they should be regarded to have septic shock.88 Table 1 
includes definitions of SIRS, hypotension, hypoperfusion, and organ failures. 
The Surviving Sepsis Campaign (SSC) Guidelines Committee has updated 
and specified the symptoms and diagnostic criteria for severe sepsis, but the 
aforementioned basic principals have not been changed.29,89-91 Another 
concept for staging sepsis, called PIRO, was published in 2003.89,92 The 
elements of the PIRO concept are: Predisposition (premorbid illness, age, 
and comorbidities); Insult (injury, infection); Response (signs of sepsis); and 
Organ dysfunctions.89 In future PIRO may develop into a reliable score for 
staging sepsis and to predict hospital mortality outcome in patients with 
sepsis, but further validation and customization of the model is needed.93-96  
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Table 1. Definitions of systemic inflammatory response syndrome (SIRS), 
hypotension, hypoperfusion, and organ dysfunction 88 
 Definition 
SIRS Temperature 38?C or <36?C 
Heart rate >90/minute 
Respiratory frequency >20 breaths/minute or pCO2 
<4.3kPa 
Leukocytes >12 x 10 /l or <4x10 /l or >10% immature 
(bands) forms 
Hypotension Systolic blood pressure <90mmHg or reduced ≥40 mmHg 
from baseline 
Hypoperfusion For example lactic acidosis, oliguria or alteration in mental 
status 
Organ 
dysfunction 
Altered organ function resulting in disability to maintain 
homeostasis 
 
 
2.1.2 Acute kidney injury (AKI) 
 
Acute kidney injury (AKI) is a syndrome characterized by sudden disruption 
in renal function of regulating fluid and electrolyte compositions of the body 
and excreting waste products of metabolism. The definition of AKI has been 
based on serum creatinine level and on urine output. The nomenclatures, 
acronyms, and definitions of AKI have varied extensively in previous 
literature. In 2004, Acute Dialysis Quality Initiative (ADQI) commenced the 
first unifying definition and staging of AKI by presenting RIFLE criteria, 
which consist of three acute (Risk, Injury, and Failure) and two clinical 
outcome categories (Loss and End-stage renal disease) for kidney injury.97 
The RIFLE criteria defined and staged AKI by elevation in serum creatinine 
from baseline, by decrease in estimated glomerular filtration, and by 
diminished urine output. To increase the sensitivity of the RIFLE criteria, the 
Acute Kidney Injury Network (AKIN) published the AKIN criteria,98 which 
comprise three severity stages for AKI. The AKIN criteria modified the 
timeframe for increment of serum creatinine from 7 days to 48 hours, 
required no baseline serum creatinine, included an absolute increase in 
serum creatinine of ≥26.5μmol/l as a criterion of AKI, and staged RRT-
treated patients to the worst AKI stage. Thus far, RIFLE and AKIN criteria 
have been validated by numerous studies including more than 500,000 
patients.99 In comparison, to identify patients with AKI in the same study 
9 9
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population, the RIFLE and AKIN criteria have performed quite similary.9,100 
However, Lopes and colleagues found that the AKIN criteria showed a  
higher detection rate of AKI,101 while in the study by Joannidis and 
colleagues the RIFLE criteria identified more patients with AKI.102 The most 
recent definition of AKI, the Kidney Disease: Improving Global Outcome 
(KDIGO) criteria, is a combination of the RIFLE and AKIN criteria.35 All of 
these classifications stage AKI by the worst fulfilled criteria, either urine 
output or creatine. The definition and stages of RIFLE, AKIN, and KDIGO 
criteria are presented in Table 2. 
 
Severe sepsis associated AKI implies the fulfillment of the criteria for both 
severe sepsis88 and AKI35,97,98 simultaneously. 
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Table 2. Definition and classification of AKI by RIFLE, AKIN, and KDIGO criteria. 
RIFLE97 AKI should occur within 7 days and be sustained for >24 hours. 
 Serum Creatinine (SCr)/ GFR Urine output 
Risk Increased SCr x 1.5 or  
decrease in GFR >25% 
<0.5ml/kg/h for ≥6 hours 
Injury Increased SCr x2 or  
decrease in GFR >50% 
<0.5ml/kg/h for ≥12 hours 
Failure Increased SCr x 3 or SCr 
≥353.6 μmol/l with acute increase 
of ≥44.2μmol/l or 
decrease in GFR >75% 
<0.3ml/kg/h for ≥24 hours or 
anuria for ≥12 hours 
Loss Complete loss of renal function for >4 weeks 
End-Stage Need for RRT for >3 months 
AKIN 98 Increase in serum Creatinine must occur <48 hours. 
 Serum Creatinine Urine output 
Stage 1 ≥26.5 μmol/l increase <48 hours or 
1.5-2-fold from baseline 
<0.5ml/kg/h for > 6 hours 
Stage 2 2- to 3-fold from baseline <0.5ml/kg/h for >12 hours 
Stage 3 >3-fold from baseline or  
≥353.6 with acute increase of  
 44.2 μmol/l or  RRT 
<0.3ml/kg/h for 24 hours or 
anuria for 12 hours 
KDIGO35 
Increase in serum Creatinine ≥26.4μmol/l within 48 hours or ≥1.5 
times baseline, which is presumed to have occurred in preceding 7 
days. 
 Serum Creatinine Urine output 
Stage 1 Increase ≥26.5μmol/l <48 hours or 
1.5-1.9 times baseline 
<0.5ml/kg/h for 6-12 hours 
Stage2  2.0-2.9 times baseline <0.5ml/kg/h for ≥12 hours 
Stage 3 >3.0 times baseline or 
≥353.6μmol/l or  
initiation of RRT 
<0.3ml/kg/h for ≥24 hours or 
anuria for ≥12 hours 
AKI acute kidney injury; AKIN Acute Kidney Injury Network; GFR glomerular filtration rate; 
KDIGO the Kidney Disease: Improving Global Outcome; RIFLE Risk, Injury, Failure, Loss and End-
stage; RRT renal replacement therapy. AKI is staged by the worst fulfilled criteria, either urine output 
or serum creatinine. 
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2.2 Evaluation of renal function 
2.2.1. Glomerular filtration rate (GFR) 
 
High renal blood flow, approximately 20% of cardiac output, is required to 
produce a large amount of glomerular filtrate to excrete waste products.103 
The amount of blood flow extensively exceeds the need of renal oxygen 
demand. Renal arteries supply blood flow to the kidneys. After multiple 
divisions of arteries, blood finally flows to a renal corpuscle and to 
glomerular capillaries through afferent arterioles. Thereafter, filtrated blood 
flows away from glomerular capillaries via efferent arterioles.104 In the renal 
corpuscle, protein-free plasma-like fluid filters from the glomerular 
capillaries into Bowman’s space (glomerular filtration). The glomerular 
filtration is dependent on the surface area and permeability of the capillaries 
and on the glomerular filtration pressure. The glomerular filtration pressure 
is glomerular capillary pressure (= capillary hydrostatic pressure moving 
fluid out of the capillary) subtracted from the plasma oncotic pressure 
(retains fluid in the capillary) and hydrostatic pressure in Bowman’s capsule 
(oppose fluid movement from the capillary).103 Resistance of the afferent and 
efferent arterioles determines the glomerular capillary pressure. The 
pressures in the renal corpuscle are illustrated in Figure 1.  
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Figure 1. Pressures in the renal corpuscle effecting glomerular filtration pressure. 
Modified from Power I, Kam P. Principles of physiology for the 
anaesthetist, 2008, with permission by Taylor & Francis Group.103 
 
 
Glomerular filtration rate (GFR) is recommended as the best measure of 
kidney function.35 GFR is measured indirectly by administering substances, 
which freely filtrate across the glomerular capillary membrane and are not 
reabsorbed or excreted by the tubules; such as inulin, iothalamate, iohexol, 
and sinistrin.105,106 GFR can be calculated according the following equation:  
 
GFR (ml/min) = Cu x Qu    
                              Cp 
 
Cu= Consentration of a substance in urine (mg/ml)  
Cp= contration of a substance in plasma (mg/ml)  
Ou= Urine flow rate (ml/min) 
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2.2.2 Estimations of GFR 
Creatinine and urine output 
 
Serum or plasma creatinine concentration and urine output are the most 
usual surrogates for GFR to detect and diagnose AKI in daily clinical practice. 
Creatinine is a late surrogate of renal function. Nearly 50% of kidney 
function is lost, before creatinine rises.  As creatinine is a functional marker, 
it does not describe renal parenchymal cell injury. In addition, age, gender, 
race, diet, hydration status, and muscle mass modify production of 
creatinine.107,108 Theoretically, changes in urine output reflect changes in 
GFR, but various etiologies, such as obstruction in urinary track and use of 
diuretic medication, can cause alteration in urine output without 
deterioration in GFR. Although oliguria has been shown to significantly 
associate with occurrence of new AKI (defined by RIFLE classification using 
solely creatinine criteria), the oliguria has only a fair predictive ability for 
subsequent new AKI (area under receiver operator characteristic curve, AUC 
0.75).109 Currently all modern AKI classifications (RIFLE, AKIN, and 
KDIGO) define and stage AKI on the basis of creatinine and urine 
output.35,97,98 
Creatinine clearance (CrCL) 
 
The clinical feasibility of GFR measurements with exogenous substances is 
poor. Creatinine clearance (CrCl) is routinely accepted as an estimate of 
GFR.103,110 Creatinine is freely filtered across the glomerulus capillary 
membrane and is not reabsorbed. Yet, it is not an optimal measurement for 
GFR estimation due to the small amount of tubular excretion of creatinine 
causing overestimation of the true GFR.108 Measurement of CrCl requires 
steady state and, thus, it is unsuitable for clinical practice for critically ill 
patients with unstable clinical conditions and changing volume status. 
Equations for estimating GFR have been developed. The most commonly 
used are Cockroft-Gault111, simplified four variable equation of the 
Modification of Diet in Renal Disease (MDRD)107, and the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI)112 formulas. These equations 
adjust patient’s creatinine value to age, weight, gender, and ethnic group. 
Table 3 presents these three equations. 
21 
 
The Acute Dialysis Quality Initiative has recommended the MDRD 
equation.97 According to a recent review the CKD-EPI creatinine equation is 
more accurate than MDRD113 and the CKD-EPI creatinine equation is also 
recommended for estimating GRF by the KDIGO 2012 clinical guideline for 
chronic kidney disease.114 However, no single equation is optimal across all 
populations and all equations cause bias. 113,115 
 
 
Table 3 Equations of the glomerular filtration rate (GFR) 
Cockroft-Gault 
equation111 
CrCl (ml/ml) = (140-Age) x Weight    (x 0.85 if female) 
                                  72 x Cr 
MDRD 
equation107 
GFR (ml/min/1.73m2) = 186 x Cr (-1.154) x Age(-0.203) x  
(0.742 if female) x (1.212 if Afro-Americans) 
CKD-EPI 
equation112 
GFR (ml/min/1.73m2) = 141 x min (Cr/?,1)? x max(Cr/?,1)-1.209x 
0.993age x (1.018 if female) x 1.159 if Afro-Americans) 
 
Cr = serum creatinine (mg/ml); ? = 0.9 for male / 0.7 for female; ? = -0.411 for male / -0.329 for 
female; min= minimum SCr / ? or 1; max = maximum SCr / ? or 1 
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2.3. Incidence of septic AKI and severe sepsis 
In general ICU patients, the incidence of AKI varies from 6% up to 67% 
depending on the study population.9,17,116-128 Among critically ill patients the 
aetiology of AKI is multifactorial and severe sepsis is the most common 
contributing factor to AKI. Of critically ill patients with AKI, 20%-67% have 
concomitant sepsis, severe sepsis, or septic shock.9,116,121,122,125,126,129 The 
incidence of severe sepsis associated AKI treated in the ICU has varied from 
13% up to 78% depending on the severity of sepsis and definition of AKI.8-23 
In the FINNSEPSIS study3, acute renal failure (renal SOFA points ≥3) was 
present in 23% of patients with severe sepsis and in the SOAP study in 
51%130. The proportions of patients with AKI among septic patients treated in 
the ICU are shown in Table 4. 
  
The population-based incidence of severe sepsis associated AKI is uncertain. 
The FINNAKI study, covering 85% of the adult population in Finland, 
reported the population-based incidence of ICU-treated AKI as 0.746/1000 
adult population/year.121 Previously only two studies have reported the 
population-based incidence of ICU-treated AKI to be 2.147/1000 adult 
population/year 131 and 2.9/1000 adult population/ year132. Regrettably, 
those studies represented only a specific region in Scotland131 and a single 
county in the U.S. 132  
 
The proportion of patients with severe sepsis in ICU admissions has been 
approximately 9% to 12%1,2,4,5 and the population-based incidence of severe 
sepsis has varied from 0.46 to 3.00 /1000 adults/year.1,133-138 According to 
the FINNSEPSIS study, the population-based incidence for severe sepsis was 
0.38/1000 adult/years in 2005 in Finland. The number of patients with 
sepsis has shown to increase globally.5-7,136 The annual increment of 8.2% 
(between 1993 and 2003)6 and 17.8% (between 200o-2007)7 in hospitalized 
patients with severe sepsis has been reported in the U.S. Likewise, an 
increasing trend in ICU-treated patients with severe sepsis has been found in 
Australia and New Zealand and in France.1,5,26 However, despite the 
increasing incidences of both severe sepsis and AKI, the proportion of septic 
AKI in ICU-treated AKI has not been found to increase.26 
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2.4 Pathophysiology of septic AKI 
The understanding of the pathophysiology of septic AKI is markedly limited 
due to scarce histopathological data and limited abilities to measure the renal 
blood flow in patients during severe sepsis associated AKI. The knowledge on 
the pathophysiology of septic AKI is mainly based on experimental studies. 
Based on observations in animals141,142 and humans25 with hypodynamic 
shock, ischemic insult due to reduced renal blood flow and subsequent renal 
vascular vasoconstriction has been considered as the main cause of the septic 
AKI.43 However, recent experimental44-49 and human studies42,50,51 have 
shown that renal blood flow is preserved or even increased during severe 
sepsis suggesting that alteration in glomerular filtration pressure and in 
intrarenal distribution of blood flow are more important factors in the 
pathophysiology of septic AKI than renal ischemia. Sparse findings of tubular 
injury in renal histopathological findings have supported this theory in 
animal studies.52,54 In line with this, histopathological evidence of acute 
tubular necrosis (ATN) was observed in only 22% of patients with sepsis 
associated AKI54 and post-mortem kidney biopsies of patients with sepsis 
associated AKI have shown heterogeneity of the histopathological changes.53 
Currently, the pathophysiology of septic AKI is suggested to be multifactorial 
including alterations and disturbances in glomerular filtration pressure and 
in intrarenal distribution of blood flow, inflammation, oxidative stress, 
apoptosis, microcirculatory disorders, mitochondrial dysfunction, and organ 
cross-talk.143,144  
2.4.1 Alterations in renal blood flow 
 
Under physiological conditions, autoregulation of regional blood flow 
ensures constant organ blood flow within an organ specific range of blood 
pressure. Below the autoregulation threshold, organ blood flow decreases 
almost linearly.145 The optimal goal for MAP during severe sepsis and septic 
shock to restore renal blood flow and prevent kidney injury is unclear. SSC 
guidelines suggest targeting a MAP ≥ 65 mmHg during severe sepsis.29 The 
results of studies regarding optimal blood pressure during severe sepsis have 
been versatile. In patients with septic shock, MAP levels between 72 and 
82mmHg have been associated with lower incidence of AKI.57 In another 
study, MAP below 75 mmHg was found to predict the need of RRT56. A 
recent randomized, controlled trial (RCT) comparing a low MAP-target (65-
70mmHg) to a high MAP-target (80-85 mmHg) among patients with septic 
shock found no difference in the overall rate of renal dysfunction between 
25 
different MAP-target groups.146 A difference is only seen in patients with 
chronic hypertension, where the incidence of a doubling of the plasma 
creatinine or use of RRT was reported to be lower with higher MAP-target 
when compared to the low MAP-target group. 146 The observed MAP-levels 
exceeded the targeting MAP-levels in both groups, however. In the low-target 
group (65-70mmHg), MAP-levels were mainly between 70 and 75 mmHg, 
and in the high-target (80-85 mmHg) group between 80 and 90mmHg.146 
Lower MAP has also been shown to associate with increased incidence of AKI 
in septic pigs.147 To the contrary, no beneficial effect of norepinephrine 
increased MAP, from 65 to 85 mmHg, was found on renal function or in 
blood lactate levels among patients with septic shock.148,149  
 
In septic AKI, renal blood flow has been shown to vary by cardiac output 
referring to impairment of autoregulation.48,150 Decreased renal vascular 
resistance and increased renal blood flow with simultaneously diminished 
GRF with increased serum creatinine have been observed in experimental 
studies with hyperdynamic sepsis. 44,45,48,49,151-153 A review of 159 animal 
studies with induced sepsis concluded that the renal blood flow was 
preserved or increased and the cardiac output was the predictor of renal 
blood flow in two-thirds of studies.48 Likewise, in patients with sepsis-
associated AKI renal blood flow has been found to be normal or increased by 
using a renal vein thermodilution catheter.50  
 
In the absence of diminished renal blood flow, the reduced GFR is suggested 
to be a consequence of decreased glomerular filtration pressure caused by  
dilatation of both the afferent and efferent glomerulus arterioles with more 
intensive dilatation in the efferent arteriole.154 This view has been supported 
by administration of angiotensin II153 and arginine vasopressin155,156 in severe 
sepsis. Infusion of angiotensin II, a vasoconstricting hormone with 
preferential effect on efferent arteriole, in hyperdynamic septic sheep 
restored renal haemodynamic to normal with a subsequent marked increase 
in urine output and an enchanced creatinine clearance.153 Similarly, 
administration of arginine vasopressin improved urine output and creatinine 
clearance in septic sheep155 and in patients with septic shock, has been 
associated with decreased progression of AKI and reduced risk of RRT.156 
However, controversial results have been reported. Reduced renal blood flow 
despite maintained cardiac output has been found in septic pigs with AKI 
referring to uncoupling between systemic (reduced) and renal (increased) 
vascular resistance.157 Septic pigs with AKI had greater inflammatory and 
oxidative stress suggesting that development of septic AKI could be induced 
by both inflammation and alterations in renal circulation.157  
 
 26 
Non-invasive, reliable, and repeatable methods to measure renal blood flow 
are unavailable. Direct measurement of renal blood flow with a percutaneous 
thermodilution catheter is overly invasive for clinical use. Renal Doppler 
ultrasound is a promising, noninvasive, reproducible, and simple tool, which 
may be used to assess the renal vascular resistance.150,158 High renal arterial 
resistive index (RI) has been observed in patients with septic shock and 
development AKI.159,160 In addition, a significant decrease in RI has been 
observed when increasing MAP from 65 yo 85 mmHg with norepinephrine 
during septic shock.42 However, the value of a single RI measurement to 
predict septic AKI has proven to be insufficient.160 Another noninvasive 
method is cine-phase contrast magnetic resonance imaging (MRI), which has 
shown diminished renal fraction of cardiac output.51,150 Although cine-phase 
MRI is accurate, it is highly time-consuming and logistically difficult, 
especially for critically ill patients with multiple organ supportive treatments, 
such as mechanical ventilation, RRT, and invasive haemodynamic 
treatments. 
 
Taken together, reduced renal blood flow does not seem to be a uniform 
explanatory factor of development of AKI during severe sepsis. In addition, 
considerable variability in renal blood flow has been observed in different 
phases of septic AKI (development, established, or recovery) in individual 
patients.152,154  
2.4.2 Microcirculatory alterations  
 
In addition to numerous experimental studies, sepsis-induced alterations in 
microcirculation have also been observed in human studies.161-167 
Microcirculation comprises small vessels: arterioles, capillaries, and venules. 
Capillaries are mainly responsible for oxygen and nutrient exchange and 
elimination of cellular waste products. Perfusion heterogeneity is 
characterized by an increased proportion of intermittently or non-perfused 
capillaries leading to disturbances in oxygen diffusion with subsequent 
differences in oxygenation.168 During sepsis, these derangements in the renal 
microcirculation (for example sluggish blood flow and shunting) have been 
described to cause oxidative stress.143 The disturbances in microcirculation in 
patients with sepsis have been shown to associate independently with 
mortality163,164,169 and with the development or progression of organ 
dysfunction.164,170 The higher MAP-level from 65 to 85 mmHg has been 
observed to improve the microcirculation assessed with near-infrared 
spectroscopy, increased mixed venous blood oxygen saturation (svO2) and 
reduced blood lactate concentration.165 
27 
2.4.3 Inflammation  
 
Experimental and human studies have emphasized the importance of the 
redundant inflammation reaction in the development of severe sepsis 
associated AKI.14,171-175 The first-line host defense for pathogen is innate 
immunity, which recognizes pathogens by pathogen recognition receptors, 
including Toll-like receptors (TLRs).171,176 TLRs recognize pathogen- and 
damage-associated molecular patterns (PAMPs and DAMPs) with 
subsequently release of cytokines, such as tumor necrosis factor ? (TNF-?), 
IL-6, and interleukin-8 (IL-8) into the circulating blood.143,144,176 Higher 
blood levels of IL-6 have been reported in patients with severe sepsis 
associated AKI, compared to patients without AKI.14,20,172 TNF-? injures 
tubular cells directly and soluble TNF-receptor levels have been found to be 
independently associated to mortality among patients with septic AKI.177 
Inflammatory stimuli increase the production of nitric oxide (NO) by 
activation of inducible NO (iNO). The role of NO is both beneficial and 
detrimental during sepsis. NO is necessary for the maintenance of the renal 
blood flow during sepsis.178 However, overexpression of NO inhibits 
mitochondrial respiration leading to cell damage.143 In addition, the 
overproduction of NO causes disturbances in microcirculation, which may 
lead to shunting, sluggish blood flow, hypoxia, and further amplification of 
the inflammation signal.143,179  
2.4.4 Apoptosis 
 
Under physiological conditions, mitosis and apoptosis (genetically 
programmed cell death) are in balance.176 The role of apoptosis in septic AKI 
is controversial. In post-mortem examinations, signs of apoptotic processes 
were observed in proximal and distal tubules of every patient with septic 
shock53; and in endotoxin induced AKI, apoptosis has been found in tubular 
cells.180 Based on the important role of the caspase enzyme in development of 
apoptosis, several studies have found that caspase inhibitor prevented 
apoptosis with a simultaneous decrease in the inflammation in the 
kidney.181,182 Controversially, the recent experimental study has found no 
sign of increased apoptosis in septic AKI.52 Thus, the clinical significance of 
apoptosis in septic AKI remains unclear. 176,183 It has been suggested that to 
benefit of an individual cell survival, the cellular energy consumption is 
reprioritised and cellular metabolism is downregulated resulting in organ 
dysfunction.184 
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2.4.5 Mechanical ventilation 
The harm that mechanical ventilation causes to the kidneys is increasingly 
recognized. In experimental studies, mechanical ventilation with high tidal 
volume has been found to associate with changes in epithelial cells, renal 
dysfunction, and greater tubular apoptosis.185,186 Similarly, ventilation with 
high tidal volume caused increased NO with subsequent microvascular 
leakage in kidneys and proteinuria.187 
 
 
2.5 Biomarkers of septic AKI 
 
Current classifications for AKI are based on changes in serum Cr and urine 
output, which both reflect changes in kidney function and are not markers 
for kidney cell damage. The distinct pathophysiology in septic AKI may lead 
to expression of specific biomarkers in serum and urine.  
 
Neutrophil gelatinase-associated lipocalin (NGAL) is a protein released from 
neutrophils and it is also expressed in low concentrations in kidneys, lungs, 
and in gastrointestinal tissue.188 NGAL is filtered by the glomerulus and 
reabsorbed in the proximal tubule. Both plasma and urine NGAL has been 
shown to increase in acute tubular injury188,189 and in sepsis.190-193 
Significantly higher NGAL levels (plasma and urine) have been found in 
adults and children with sepsis associated AKI than in patients without 
sepsis associated AKI.191,192,194 The ability of NGAL to predict AKI in patients 
with sepsis has varied within AUCs 0.67-0.89.191,194-196 Interleukin-18 (IL-18) 
is a pro-inflammatory cytokine, which is produced by mononuclear cells, 
macrophages, and non-immune cells, including renal tubular injury.197-199 
Increased plasma IL-18 has been observed in sepsis and in numerous 
inflammatory diseases, such as arthritis, inflammatory bowel diseases, 
psoriasis, and multiple sclerosis.200 Higher urinary IL-18 levels have been 
found in patients with septic AKI than in patients with non-septic AKI.201,202 
Cystatin-C is a surrogate of GRF. It is freely filtered by the glomerulus and 
subsequently reabsorbed completely in the proximal renal tubule.200 Thus, 
the presence of cystatin-C in urine may indicate tubular epithelial damage. 
Among patients with sepsis, the urinary cystatin C has been shown to predict 
AKI with an AUC value of 0.71.203 Further validation and clinical studies of 
all the new biomarkers of AKI are needed, especially among critically ill 
patients with severe sepsis.  
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2.6 Risk factors of septic AKI 
Severe sepsis is the dominant risk factor for AKI in critically ill patients and 
approximately half of severe sepsis patients have concomitant AKI.9,11-14,16-
18,20,22-24,140 While assessing the patient’s risk of developing AKI the intensity, 
severity, and duration of exposure should be considered, as well as patient-
related risk factors.35 Table 5 lists the factors found to associate with higher 
risk of AKI in patients with sepsis.  These risk factors for AKI are identical for 
all critically ill patients. 
 
Table 5. Risk factors for AKI in patients with sepsis 
Patient-related risk factors 
Advanced age 12,16,23,204 
High body mass index 12,18 
Co-morbidities  
 Chronic kidney disease 12,23 
Chronic obstructive pulmonary disease12 
 Coronary artery disease12, heart failure12, hypertension 23 
Diabetes12,23,204 
 Ethanol abuse12 
 Hematologic malignancy12  
 HIV/AIDS12 
 Liver failure12,204 
 
Use of angiotensin converting enzyme inhibitor or angiotensin receptor 
blocker18,23 
Low baseline GFR18,23 / higher baseline creatinine23,204 
 
Risk factors related to critical illness 
Administration of hydroxyethyl starches30,32,33,204,205 
Blood transfusions18 
Cardiac/thoracic surgery204 
Delay in initiation of an effective antimicrobial treatment18 
Greater aberrancies in acute physiology (in haemodynamic, respiratory rate, and 
Glasgow Come scale) and in laboratory measurements (leukocytes, bilirubin, 
lactate, and pH),24 
Higher severity of illness scores12,16,23,24,204 
Increased intra-abdominal pressure206-209 
Medical admission24 
Positive blood culture23 
Source of infection: Abdominal12,18 or genitourinary infection12 
Use of iodinated contrast dye23,204 
Use of vancomycin,35,210 amphotericin B35, furosemide35, aminoglycosides35 
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In addition to increased risk of AKI, hydroxyethyl starches (HES) have been 
reported to associate with an increased risk of RRT in patients with 
sepsis.30,32,33,204,205 Recent meta-analysis have reported a relative risk of 1.36 
to 1.41 for RRT among patients with sepsis receiving HES.31,34,211 
Interestingly, the use of 20% human albumin has also been suggested to 
associate with risk of AKI in one study.204 
 
The renal perfusion pressure is decreased by increased intra-abdominal 
pressure (IAP). In critically ill patients the threshold of IAP for predicting 
AKI has been found to be as low as 12 mmHg. 207 In patients with septic 
shock, increased IAP has been associated with increasing serum creatinine 
levels.209  
 
Prolonged hypotension (defined MAP< 65 mmHg or a systolic pressure <90 
mmHg) prior to initiation of antimicrobial treatment,12 and MAP levels 
below 75-82 mmHg have been shown to increase the risk of renal failure.55-57 
The critical MAP threshold for development of AKI among patients with 
severe sepsis has been discussed in detail in the chapter on Pathophysiology 
of septic AKI (section 2.4). 
 
 
2.7 Treatment of septic AKI 
Treatment of septic AKI includes effective treatment of severe sepsis and 
supportive treatment of AKI. Guidelines for management of severe sepsis 
and septic shock (SSC guidelines) were initially published in 2004 90, and 
have been revised in 200891 and 2013.29 These guidelines comprise detailed 
recommendations on the administration of adequate antimicrobial 
treatment, of early resuscitation of hemodynamic, and of supportive 
therapies.29 Up to date, no curative therapy for septic AKI exists and the 
treatment is mainly supportive, focusing on the avoidance of known risk 
factors for septic AKI.  
2.7.1 Antimicrobial treatment of infection 
 
Administration of an effective antimicrobial therapy within an hour after the 
onset of hypotension has been found to reduce hospital mortality in patients 
with septic shock.212 A delay in antimicrobial treatment has been associated 
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with increased risk of AKI18 and mortality.213-215 Adequate antimicrobial 
dosage adjustment for patients with severe sepsis associated AKI is 
challenging, especially in RRT-treated patients. In addition to alteration in 
renal function, fluctuating volume status, disturbances in haemodynamics, 
and decreased drug protein binding further complicate drug dosing.216 Many 
antimicrobial drugs are significantly cleared by RRT and availability of 
therapeutic drug monitoring is limited with the exception of vancomycin and 
aminoglycosides. A growing body of evidence has shown that current dosing 
regimens are not adequate in critically ill patients. A meta-analysis including 
14 studies with 1229 patients treated with a ?-lactam antibiotics concluded 
that extended or continuous infusion resulted in lower mortality compared to 
short-term infusion in hospitalized patients with various infections 
(pneumonia, abdominal and genitourinary infections, and ICU acquired 
infections).217 Among patients with severe sepsis not treated with RRT, an 
improvement in clinical cure (disappearance of symptoms related to the 
infection) has been found with continuous infusion of a ?-lactam.218 Yet, no 
difference in hospital survival was found.218 Insufficient concentrations of ?-
lactam antibiotics have been demonstrated with standard dosage regimens in 
19% up t0 41% of critically ill patients, including RRT-treated patients219, and 
underdosing of ?-lactam antibiotics has been found to increase the risk of 
fatal outcome.220 Therapeutic targets of vancomycin have been more 
consistently achieved with continuous infusion compared to intermittent 
dosing in critically ill patients.221,222 The increased intensity of continuous 
renal replacement therapy (CRRT) was associated with a need for higher 
dosage regimens in order to achieve sufficient vancomycin concentration.222. 
Guidelines regarding drug dosing in acute kidney diseases are scarce and 
mainly modifications of guidelines for chronic kidney disease (CKD) 
patients.216 In addition to antimicrobial treatment, source control such as 
drainage of an abscess debridement of infected tissue and removal of 
potentially infected device should be sought and intervention should be 
undertaken, when needed.  
 
2.7.2 Treatment of haemodynamic dysfunction 
Fluids 
 
None of the currently available fluids is ideal for resuscitation of patients 
with severe sepsis associated AKI. Higher mortality rate30,211 and need for 
RRT30-33,204,211 have been reported in patients with severe sepsis receiving 
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HES. Yet, controversial results have been reported. No association between 
use of starches and renal dysfunction, RRT, or mortality has been found in 
patients with severe sepsis or septic shock.223,224 Use of HES has also been 
reported to be associated with an increased number of red blood cell 
transfusions.30-32,34,204,211 Guidelines have advocated not using HES for fluid 
resuscitation among patients with severe sepsis or patients with AKI.29,35 
Increased risk of AKI and decreased survival has been found in critically ill 
patients with hypoalbunemia.225 Albumin may have some unproven 
beneficial effect in patients with severe sepsis or septic shock when 
substantial amount of crystalloids have already been administered.29 A post-
hoc, non-randomized subgroup analysis (in patients with severe sepsis) of 
the SAFE (Saline versus Albumin Fluid Evaluation) study suggested 
potentially reduced mortality in patients resuscitated with albumin 
compared to those receiving saline (30.7% vs. 35.3%, P=0.09).226 
Administration of albumin did not impair renal function.227 A meta-analysis 
concluded that the use of albumin for fluid resuscitation of patients with 
sepsis was associated with reduced mortality compared to other fluids such 
as Ringer lactate, 0.9% saline, 6% HES, 10% Pentastarch, Hetastarch and 
gelofusine.228 However, a multicenter, open-label trial with 1818 patient with 
severe sepsis resuscitated with albumin or crystalloid found no beneficial 
effect of albumin on renal SOFA score, on need for RRT, or on 28 or 90 day 
mortality rates.229 Recently, excess chloride load has reported to have 
adverse effects in critically ill patients, including an increasing risk of AKI 
and need for RRT. 230,231 Thus, balanced solutions such as Ringer’s and 
Hartmann’s solutions might be more suitable for fluid resuscitation in 
critically ill patients with increased risk of AKI.232 
 
Little evidence exists regarding the optimal amount of fluid to reach the 
targets. Strikingly, reduced mortality rate has been found in febrile African 
children, who were withheld standard fluid administration with either 0.9% 
saline or 5% albumin solution.233 Thus, concerns about the previously used 
liberal fluid therapy have arisen, as excess fluid accumulation has been 
shown to be associated with adverse outcome in septic shock,234 in patients 
with AKI,235 in critically ill RRT-treated patients,236 and  in development of 
AKI in surgical ICU.237 Therefore, liberal administration of fluids is suggested 
to be avoided and administration of fluids should be guided by evaluation of 
patient’s fluid status and fluid responsiveness (changes in CO after 
administration of fluid bolus).238 Positive fluid responsiveness has been 
defined as ≥15% increase in CO or stroke volume after administration of 
fluid.239,240 
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Vasoactive treatment 
 
Administration of vasoactive therapy is often required to correct persistent 
hypotension and to retain adequate blood pressure. Of the patients with 
severe sepsis associated AKI from 56% up to 86% have received vasoactive 
treatment.12,13,16,20,24,58  
 
Norepinephrine is a potent vasoconstrictor that acts via ?-adrenergic 
receptors. In experimental studies, marked renal vasoconstriction and 
increased renal vascular resistance have been observed after infusion of 
norepinephrine into renal artery36,37 or with intravenous high doses (up to 
1.6μg/kg/min) of norepinephrine.38 Decreased vascular resistance with 
increased renal blood flow has been found with lower doses of 
norepinephrine (0.2-0.4μg/kg/min).39 In human studies, norepinephrine has 
been shown to increase creatinine clearance and urine output in septic 
shock40,41 and to decrease the renal resistance index assessed by Doppler 
ultrasonography.42 However, excess augmentation of MAP by 
norepinephrine has led to increased renal resistance42 and increasing MAP 
over 70mmHg by vasopressors has increased the risk of circulatory failure, 
metabolic acidosis, and thrombosytopenia.56  
 
For years “low-dose” dopamine (<5μg/kg/min) has been used for its 
presumed renoprotective effects based on findings in experimental studies 
and healthy humans.241-243 The protective effect on dopamine has not been 
confirmed in clinical studies.244-248 The results of current studies have not 
supported the use of dopamine, as it does not prevent AKI, reduce need for 
RRT, or improve outcome, and may even worsen renal perfusion.246,249-251 
Accordingly, SSC guidelines recommend norepinephrine as a first choice 
vasopressor and that “low-dose” dopamine should not be used.29 In the 
presence of myocardial dysfunction the treatment with dobutamine is 
recommended. Recent experimental and human studies have reported 
beneficial effects (increased microvascular blood flow, and improvements in 
organ functions) of levosimendan in sepsis252-255, but further investigations 
are needed.  
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2.7.3 Renal replacement therapy (RRT) 
 
Of the patients with septic AKI, 4% to 70% of patients receive 
RRT.8,11,16,17,20,23,24,58,59 Excluding the absolute indications for RRT such as 
hyperkalaemia, severe metabolic acidosis, overt uraemia, fluid overload with 
pulmonary oedema, and specific drug intoxications190, the decision to initiate 
RRT is mainly based on clinical judgment. The B.E.S.T. (Beginning and 
Ending Supportive Therapy for the Kidney)- study reported marked practice 
variation for RRT worldwidely256 and corresponding results have been found 
among European intensivists.257 In these studies, oliguria256,257, high serum 
or plasma urea or creatinine,256,257 fluid overload,256,257 metabolic acidosis,256 
and hyperkalaemia257 were the main indications for initiation of RRT. 
Despite a growing number of studies, no broad guidelines regarding timing, 
indication, modality, or dose of RRT exist.  
 
The definitions of early and late initiation of RRT are based on different 
thresholds of urea and creatinine levels, or on varying time frames. Early 
hemofiltration has reported to prolong the need for mechanical ventilation 
and vasoactive treatment.258,259. However, patients with sepsis associated 
AKI treated with early RRT (defined as urea <35.7 moll/l, inception of CRRT 
≤24 hours after diagnosing sepsis, or by time from ICU admission/initiation 
of vasopressor infusion to initiation of RRT) have survived better.260-263 
Recent reviews264,265 and a meta-analysis266 concluded that critically ill 
patients may benefit from early RRT. Instead of single laboratory values or 
timeframes, the decision to initiate RRT is advocated to be based on wider 
clinical evaluation of the patient with concern for fluid balance and nutrition, 
severity of underlying diseases, degree of other organ dysfunction, and 
likehood of renal recovery.35 
 
Studies from the 1990s reported greater haemodynamic stability and 
suggested favorable survival with CRRT compared to intermittent 
haemodialysis (IHD) in critically ill patients.267-271 Recent studies have not 
supported this theory,268,272,273 however, patients with unstable 
haemodynamics have been converted from IHD groups to CRRT, leading to a 
significant bias.272,274 Better achievements of fluid balance targets have been 
shown with CRRT than IHD.275 As CRRT is suggested for haemodynamically 
unstable patients35, it is a reasonable modality of patients with severe sepsis 
or septic shock. Of the prescribed RRT, European intensivists administered 
CRRT to patients in 88% of cases 257  
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Uncertainty of the optimal dose of RRT for patients with severe sepsis 
associated AKI persists. Ronco and colleagues published the landmark study 
regarding the dose of RRT in critically ill patients.276 In a subgroup analysis 
of patients with sepsis they found that effluent rate over 45ml/kg/h was 
associated with improved outcome.276 The randomized RENAL (The 
Randomized Evaluation of Normal versus Augmented Level), the ATN 
(Veterans Affairs/National Institutes of Health Acute Renal Failure Trial 
Network), and the observational DO-RE-MI (DOse REsponse Multicentre 
International collaborative Initiative) studies showed no reduction in 
mortality by intensive RRT.277-279 Thus, a CRRT dose of 20-25 ml/kg/h is 
recommended by KDIGO35 and other  reviews regarding AKI or CRRT.60,280  
 
It has been theoretized that high-volume hemofiltration (HVHF) could be 
beneficial in septic AKI by purifying inflammatory mediators from the 
bloodstream.281 Previous small, single centre studies reported decreased 
vasopressor doses282 and improvements in haemodynamics in patients 
treated with HVHF.283,284 The IVOIRE study [high-volume (70ml/kg/h) vs. 
standard-volume (35 ml/kg/h) hemofiltration] found no reduction in 28-day 
mortality and in duration of mechanical ventilation, RRT, or vasoactive 
treatment.62 Accordingly, HVHF is not recommended for treatment of septic 
shock associated AKI.62 This recommendation was supported by a meta-
analysis of four RCTs. 63 
 
 
2.8 Outcome  
2.8.1 Short and long-term mortality 
 
Most studies have reported short-term mortality rate (ICU or hospital 
mortality) or mortality rate at 28 days after ICU admission. The short-term 
mortality rates for severe sepsis associated AKI have ranged from 16% to 
70%. 8,10-12,16,18,20-22,24,25,27,28 Few reported long-term mortality rates have 
varied from 36% up to 67%.11,12,14 Mortality rates in patients with severe 
sepsis-associated AKI from recent studies are presented in Table 6. Patients 
with septic AKI have increased short-term mortality compared to non-septic 
AKI8,10,24 and to patients with sepsis but without AKI.10,11,13,14,16,18,20,28  
 
Multiple studies have reported an increased mortality rate for hospital 
survivors after critical illness up to 2-10 years after hospital discharge.285-290 
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Among critically ill patients, AKI has been shown to increase long-term 
mortality.25,72-79 Even mild AKI (KDIGO stage 1) has been found to reduce 10-
year survival in critically ill patients.291 In Finland, mortality rates of 57% at 1 
year, and 70% at 5 years, have been observed among RRT-treated patients.78 
 
Table 6.  Mortality rates of sepsis associated AKI 
 
Study 
design 
Severity 
of sepsis 
Patients 
with AKI 
Mortality (%) 
ICU Hospital 28- 
day 
90-
day 
Neveu 199625 P, M sepsis 157  74.5   
Hoste 20038,28 R, S sepsis 30 53.3 56.7 - - 
Bagshaw 
200724 
P, M sepsis 833 - 
70.2 - - 
Bagshaw 
200810 
R, M sepsis 14 039 19.8 
29.7 - - 
Oppert 200811 P, M Severe 
sepsis 
166 64.6 
67.3 - 67.3 
Bagshaw 
20092 
R, M Septic 
shock 
3 373a 53.4 
59.5 - 58.4 
Lopes 200913 R, S sepsis 99 - 52.5 - - 
Yegenaga 
201016 
P, D sepsis 79 - 
65 - - 
Plataki 201118 
 
P, S Septic 
shock 
237 - 
48.5 - - 
Kim 201220 R, S Severe 
sepsis 
183b - 
- 59.2 - 
Payen 201220 P, M Severe 
sepsis 
129 - 
- 32.6 - 
Gurjar 201321 R, S sepsis 126 52 - - - 
Legrand 
2013237 
R, S Severe 
sepsis 
69 39 
45 38 - 
Suh 201323 R, S sepsis 573  16.4   
White 201322 P, S sepsis 161 17 24 - - 
Peng 2014140 R,S sepsis 101 - - 46.5 - 
 
D dual center; M multiscenter; P prospective; R retrospective; S single center; apatients with septic 
shock and persistent hypotension prior to initiation of antimicrobial therapy bdefined by RIFLE 
criteria within first 72 hours in the ICU 
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2.9 Predictive models 
Predictive models have been used in intensive care to classify individual 
patients on the basis of severity of illness and, thereafter, to predict the risk 
of hospital mortality of a group critically ill patients.64-71 In addition, 
predictive models have been used to evaluate the ICU performance and in 
benchmarking, to assess resource use, and to include more homogeneous 
patients groups in clinical trials. 292-294 After careful consideration supported 
by clinical judgement, these models may be useful in clinical-decision-
making and for estimation of the prognosis of an individual patient.  
2.9.1 General ICU models 
 
The two most common general predictive models for hospital mortality for 
ICU-treated patients are Acute Physiology and Chronic Health Evaluation 
(APACHE)64 and Simplified Acute Physiology Score (SAPS)68. Both of the 
models have been updated several times; APACHE II-IV65-67, and SAPS II69 
and 3.70,71 All of these models include variables regarding chronic health 
status preceding acute illness, physiologic measurements of acute illness, and 
type of ICU admission (elective/emergency and medicine/operative). For the 
physiologic measurements, the worst value within the first 24 hours in the 
ICU is included in the models 65-67,69,295,296 except SAPS 3,70,71 in which the 
timeframe for physiological values is limited for one hour preceding and after 
ICU admission. The models need to be separately customized for different 
geographical regions for better performance. The SAPS 3 model provides 
customized equations for several geographical regions (Australasia, 
Central/South America, Mediterranean, North America, and 
Central/Western/Eastern/North/Southern Europe).70,71  
 
Organ dysfunction score, the Sequential Organ Failure Assessment (SOFA), 
has been primarily developed to describe the organ dysfunction in patients 
with severe sepsis, but later it has been applied in non-septic patients as 
well.297 The function of six organs (respiratory, cardiovascular, renal, hepatic, 
central nervous system, and coagulation) are assigned daily according to the 
severity of dysfunction (normal to organ failure). Although the SOFA score 
has not been developed to predict mortality, a review comprising 18 studies 
concluded that in predicting hospital mortality, SOFA-based models 
performed only slightly worse than APACHE II or III scores and were 
competitive with SAPS II.298 For predicting hospital mortality, the SOFA 
score has been used in a heterogeneous way: SOFA score on admission or at 
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a predefined time during ICU stay, the max SOFA score (highest daily SOFA 
score), total max SOFA score (sum of the highest scores of each organ system 
during the entire ICU stay), mean SOFA score (average of all total SOFA 
score), and delta SOFA (difference in predetermined time point during ICU 
stay).298 
 
2.9.2 AKI-specific predictive models 
 
Most AKI specific models provide estimations of the hospital mortality80-
82,299 or 60-day mortality.86,300,301 Some of these models are obsolete due to 
variations in definition of AKI and poor performance in external 
validation.59,84,302,303 In addition, one model is based on data on only RRT-
treated patients,86 and therefore, does not apply to patients with less severe 
AKI. Despite increased long-term mortality among critically ill patients with 
AKI,25,72-78 AKI-specific predictive models for long-term mortality are 
lacking. Table 7 summarizes characteristics of the models including the 
predictive factors.  
 
AKI-specific models for hospital mortality 
 
The model by Liano et al80 has been based on data from a single centre and 
AKI has been defined as an abrupt rise in serum creatinine over 177 ?mol/l 
The development cohort of this model comprised 228 patients and the model 
was internally validated. Thereafter the model has been externally validated 
resulting in AUC-values ranging from 0.7 to 0.78.299,304  
 
Stuivenberg Hospital Acute Renal Failure (SHARF) score81 has also been 
derived on data on patients with AKI in a single centre. AKI was diagnosed as 
serum creatinine exceeding 177 ?mol/l or an increase of more than 50% in 
patients with CKD. The model comprises two measuring points: time of 
diagnosis AKI (T0) and 48 h later (T48)81. Both measuring points comprise 
the same predictors, which are presented in Table 7. The AUC-values of the 
model were 0.87 (T0) and 0.90 (T48) in the development cohort81, but in 
multicentre patient population only  0.67 (T0) and 0.78 (T48)82. Therefore, 
the models were customized by including additional predictors: serum 
bilirubin, presence of sepsis and hypotension82. The discriminative power of 
customized SHARF score improved yielding AUC values of 0.82 (T0) and 
0.83 (T48)82.  
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A model by Mehta299 and colleagues was derived from prospectively collected 
data on patients with AKI treated in four ICUs. AKI was defined according 
the blood urea nitrogen (≥14 mmol/l) or serum creatinine (≥177?mol/l) 
levels and for patients with CKD a sustained rise in creatinine of ≥88?mol/l 
from baseline value was required. The AUC-value of the original model (AUC 
0.83) and the bootstrapped adjusted AUC-values (0.795-0.89) were in 
line.299 However, in external validation an AUC-value of 0.670 was yielded.85 
 
AKI-specific models for 60-day mortality  
 
Chertow et al have developed two AKI-specific predictive models for 60-day 
mortality.300,301 The first model was derived on data on patients with AKI 
with a sudden rise in creatinine of at least 88.4 ?mol/l over 24 to 48 hours. 
The AUC of the model was 0.81 in the development cohort.300 To improve the 
predictive power of the model, a new AKI-specific model with three different 
measuring points (the day of diagnosing AKI, the day of consulting 
nephrology, and the day of initiation of RRT) was developed.301 Different 
variables remained predictors at discrete time points. These variables are 
presented in table 7. The performance of the model improved over time with 
increasing AUC-values for models: day of diagnosing AKI (AUC 0.62), 
consulting nephrology (AUC 0.68), and initiation of RRT (AUC 0.72).301 
 
Predictive models for RRT-treated patients 
 
The predictive model for 60-day mortality by Demirjian comprises 21 
predictors based on the data from the ATN study.86 The bootstrapped AUC 
value of 0.85 was significantly better than the corresponding AUC-values of 
APACHE II (0.68) and total SOFA (0.69) scores.86 This new model needs to 
be externally validated before use in clinical practice.  
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The ability of the SHARF score to predict one-year mortality has been 
evaluated and the score yielded AUC values of 0.791 for T0 and 0.833 for 
T48.74 However, the score was tested among survivors of development cohort 
of the original SHARF score and hence a good performance of the SHARF 
score was to be expected. Among RRT-treated patients, increased Charlson 
co-morbidity index, presence of liver disease, higher APACHE II score, septic 
shock and need for CRRT have been found to be risk factors for one-year 
mortality.72 This model performed outstandingly with an AUC –value of 
0.83.  Validation and customizing are needed before applying these models 
to clinical use and in patients with less severe AKI.  
 
External validation of the AKI-specific models 
In external validation using the multinational database of B.E.S.T. study 
(1742 patients), none of the AKI-specific (Chertow’s, Liano’s, or Mehta’s) 
yielded an AUC-value above 0.7, which is considered satisfactory for clinical 
use.85,305. Liano’s model has also been externally validated in 238 RRT-
treated patients receiving an AUC-value of 0.78.306  
 
2.9.3 Predictive ability of general ICU-scores and AKI criteria 
among patients with AKI  
In lack of AKI-specific instrument to predict hospital mortality, general ICU-
scores (APACHE II-IV, SAPS II and 3, and SOFA scores) have been evaluated 
for their predictive ability among patients with AKI.84,85,299,301,307-310 Only the 
customized SAPS3 has presented good discrimination with AUC-values of 
0.8283 and 0.82.308 Patients with AKI have unique characteristics, which 
most probably influence the performance of general ICU score.  
 
Likewise, the predictive abilities for hospital mortality of AKI criteria 
(RIFLE, AKIN, and KDIGO) have been evaluated.304,311 AUC-value of RIFLE 
criteria was AUC 0.6 in hospitalized patients.304 Among critically ill patients 
all three definitions had comparable prediction ability for hospital mortality 
with AUC-values of 0.733-0.74 for all three classifications.311 
Prediction of long-term mortality 
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Table 7. Summary of the predictive AKI-specific models 
 Design Validation Predictors 
PREDICTIVE MODELS FOR HOSPITAL MORTALITY 
Liano 
(1993)81 
228 AKI patients  
P,S 
Internal validation ( 100 
patients)  
External validation (25 
patients) 
Age, male, nephrotoxics, oliguria, 
hypotension, jaundice, coma, 
consciousness, and assisted 
respiration 
SHARF 
(2000)82 
197 AKI patients  
P, S 
 Both T0 and T48 scores: Age, 
serum albumin, protrombine time, 
respiratory support and heart 
failure 
Mehta 
(2002)300 
851 AKI patients,  
P, M 
Internal validation, 
bootstrapping 
Age, male , BUN, Cr, hematologic 
failure, liver failure, respiratory 
failure, heart rate, and urine 
output 
SHARF 
(2004)83 
293 AKI patients  
P, M 
 Both T0 and T48 scores: Age, 
serum albumin, protrombine time, 
respiratory support, heart failure, 
serum bilirubin, sepsis, and 
hypotension 
PREDICTIVE MODELS FOR 60-DAY MORTALITY 
Chertow 
(1997)87 
257 AKI patients  
R, M 
Internal, 
bootstrapping 
Male, oliguria, total bilirubin, 
ventilation, stroke or seizure, 
acute myocardial infarction, 
immunosuppression, bicarbonate, 
and albumin 
Chertow 
(2006)88 
618 AKI patients  
R, M 
- 1) Day on AKI diagnosis: age, 
CKD, BUN, liver failure, sepsis or 
septic shock 
2) Day on consultation: age, urine 
output, Cr, BUN, liver failure, 
ARDS, platelets < 150 x 106/ l, 
sepsis or septic shock 
3) Day of initiation of RRT: age, 
urine output, Cr, BUN, liver 
failure, respiratory failure, 
platelets<100 x 106/ l, sepsis or 
septic shock 
Demirjian 
(2011)89 
1122 RRT-
patients 
 R, M  
Internal, 
bootstrapping 
Age, chronic hypoxemia, 
cardiovascular disease (angina, 
myocardial infarction, congestive 
heart failure), malignancy, 
immunosuppressive therapy, 
ischemic AKI, postoperative 
patient, at initiation of RRT: heart 
rate, MAP, daily urine volume, 
mechanical ventilation, FiO2≥0.6, 
interaction of mechanical 
ventilation and FiO2≥0.6, arterial 
pH and PaO2, Cr, bicarbonate, 
phosphate, albumin, total 
bilirubin, INR, and platelet count 
BUN blood urea nitrogen; Cr creatinine; FIO2 fraction of inspired oxygen; INR internation 
normalized ratio; M multicenter; MAP mean arterial pressure; P prospective; RRT renal replacement 
therapy; S singe centre; SHARF Stuivenberg Hospital Acute Renal Failure 
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3. AIMS OF THE STUDY 
The main aims of this study were to assess the incidence and long-term 
outcome of ICU-treated severe sepsis associated AKI in Finland and to 
identify factors predicting one-year mortality of critically ill patients with 
AKI. 
 
The specific objectives were:  
 
1. To determine the incidence and population-based incidence of severe 
sepsis associated AKI according to the new KDIGO classification in adult 
patients treated in Finnish ICUs. (I) 
 
 2. To assess possible changes in the population-based incidence of ICU-
treated severe sepsis treated in Finnish ICUs. (I) 
 
3. To evaluate the association of time-adjusted MAP and vasoactive 
treatment with development and progression of AKI among patients with 
severe sepsis, and their association with 90-day mortality. (II) 
 
4. To scrutinize the variation in use of RRT in adult patients with septic 
shock treated in different Finnish ICUs. (III) 
 
 5. To develop and validate predictive models for one-year mortality for 
patients with early AKI. (IV) 
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4. PATIENTS AND METHODS 
4.1 Patients 
For all the studies (I-IV), patients were from the FINNAKI study.121 The 
FINNAKI study was a prospective, observational, multicenter study 
conducted in 17 Finnish ICUs between 1 September 2011 and 1 February 
2012. The participating 17 ICUs comprised 5 ICUs in university hospitals and 
11 central hospital ICUs. The FINNAKI study included all emergency 
admissions and those elective postoperative ICU admissions with an 
expected stay for at least 24 hours. The following patients were excluded: 1) 
patients under 18 years of age, 2) intermediate care patients, 3) patients with 
chronic dialysis, 4) patients, who received RRT during the previous ICU 
admission, 5) transferred patients, who already included in the study for 5 
days, 6) patients without sufficient language skills or not permanently living 
in Finland, and 7) organ donors. Of the 5853 consecutive admissions 
screened for eligibility, 2901 patients were included to the FINNAKI main 
study. Figure 2 illustrates the flow chart of the substudies included in this 
work. 
 
 
Study I included consecutive patients, who fulfilled the criteria for severe 
sepsis 24 hours preceding ICU admission or within the first five days in the 
ICUs (N= 918). The statistical analyses regarding septic AKI were performed 
for these patients. Additionally, for assessment of the incidence of ICU-
treated severe sepsis, patients (N= 73), who were initially excluded from the 
FINNAKI study due to chronic dialysis or re-admitted patients receiving RRT 
during the previous ICU admission, were screened for severe sepsis 
retrospectively.  
 
For Study II including 918 patients with severe sepsis, 179 patients from four 
ICUs were excluded due to incomplete data on haemodynamics. In addition, 
patients, who fulfilled the criteria of severe sepsis later than 24 h after ICU 
admission, died within the first 5 days in the ICU, or had development of AKI 
within the first 12 hours in the ICU, were excluded. The final study 
population comprised 423 patients with severe sepsis. 
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Study III included patients, who fulfilled criteria for septic shock (N= 726). 
All FINNAKI study patients, who fulfilled the criteria for AKI during the first 
five days in the ICU, were evaluated for eligibility for Study IV.  Patients, 
who fulfilled criteria for AKI later than 24 h after ICU admission or patients 
that underwent cardiac surgery, were excluded. In addition, 40 patients from 
one ICU with incomplete data on cardiovascular SOFA score were excluded. 
The final study population comprised 774 patients with early AKI.  
For patients with multiple admissions, the first admission when criteria for 
severe sepsis was fulfilled were included in studies I-III and in study IV the 
first admission when AKI criteria were fulfilled.  
Characteristics of patients in studies I –IV are presented in Table 8. 
 
 
Table 8. Characterististics of patients in study I-IV. 
 Study I Study II Study III Study IV 
Number of patients 918 423 726 774 
Age, years 
(median,?IQR?) 
65 [54-75] 63 [51-74] 65 [55-75] 65 [55-75] 
Male n (%) 329 (36) 276 (65) 464 (64) 268 (35) 
Emergency admission  
n, (%) 894 (97) 415 (98) 704 (97) 744 (96) 
Operative admission  
n, (%) 223 (24) 108 (26) 203 (28%) 216 (28) 
SAPS II score, points 
(median, ?IQR?) 43 [34-55] 40 [32-49] 45 [35-58] 47 [36-62] 
SOFA score on day 1 
points (median, ?IQR?) 8 [6-10] 8 [6-10] 9 [7-11] 9 [7-12] 
Length of ICU stay 
days(median, ?IQR?)) 4.0 [2.1-7.6] 4.6 [2.5-8.1] 4.5[2.38.2] 3.1 [1.6-5.8] 
 
ICU Intensive Care Unit; IQR interquartile range, SAPS Simplified Acute Physiology Score; SOFA 
Sequential Organ Failure Assessment 
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4.2 Study designs and objectives 
 
Study 1 was a predefined substudy of the prospective, observational, 
multicentre FINNAKI study. The aims of this study were to assess the 
incidence, population-based incidence, risk factors for mortality, and 90-day 
mortality of ICU-treated patients with severe sepsis associated AKI. In 
addition, for the calculation of the incidence of severe sepsis, patients 
excluded from the FINNAKI study due to, 1) chronic dialysis or 2) re-
admitted patients, who received RRT during the previous ICU admission, 
were screened for severe sepsis retrospectively.   
 
Study 2 was a predetermined substudy of the FINNAKI study. This study 
evaluated the association between early haemodynamics (the first 24 hours 
in the ICU) with a new onset or worsening of AKI during the first five days in 
the ICU, with special interest in time-adjusted MAP. The time-adjusted MAP 
was calculated by dividing the area under the curve of 10-minute median 
values of actual MAP values with aggregate time of MAP registration (= first 
24 hours in the ICU or until progression of AKI). The AUCs and aggregate 
times below MAP threshold values (55 to 85 mmHg) were calculated. In 
addition, the association of vasoactive treatment and known risk factors for 
AKI were assessed. Figure 3 illustrates an example of the MAP area under 
curve (AUC) and MAP AUC under threshold 65 mmHg.  
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Figure 3. MAP values (mmHg) of an example patient with severe sepsis during the 
first 24 hours in the intensive care unit. The red arrows indicate areas below the 
threshold 65 mmHg 
 
For study 3, patients with septic shock were retrieved from the FINNAKI 
study to assess the association between the proportion of RRT use among 
patients with septic shock and 90-day mortality. The participating 17 ICUs 
were divided into low-RRT and high-RRT ICUs by a median value of 
proportion of RRT. University and central hospital ICUs were equally 
represented in both ICU groups. The differences in indications, modalities, 
and complications of RRT, and in treatment restrictions between low- and 
high-RRT ICUs were evaluated.  
 
Study 4 was a predetermined sub-study of the FINNAKI study. The aim of 
the study was to develop and validate predictive models for critically ill 
patients with AKI for one-year mortality on two time points: on admission to 
the ICU (admission model) and on the third day in the ICU (D3 model). The 
admission model only included predictors available prior to ICU admission. 
The D3 model included predictors available within the first three ICU days. 
The admission model comprised 744 patients and D3 model included 
patients with length of stay in the ICU at least three days, 398 patients. 
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Summary of study designs and the main aim of the studies are presented in 
Table 9. 
 
 
Table 9. Summary of study designs  
 Design Study 
population 
Aims 
I  Prospective, 
predetermined 
918 patients 
with severe 
sepsis 
To assess the incidence and 90-day mortality  
of severe sepsis associated AKI 
II  Prospective, 
predetermined 
423 patients 
with severe 
sepsis 
To evaluate the associations of early 
haemodynamic and vasoactive treatment with 
progression of AKI 
III  Prospective, 
predetermined 
726 patients 
with septic 
shock 
To evaluate the use of RRT and association 
between proportion of RRT use and 90-day 
mortality 
IV  Prospective, 
predetermined 
774 patients 
with AKI 
To generate predictive models for one- year 
mortality for early AKI patients 
 
 
4.3 Data collection 
Study data were retrieved from the national ICU quality database, Finnish 
Intensive Care Quality Consortium (FICC) maintained by Tieto Healthcare & 
Welfare Ltd, comprising routine dataset and supplement dataset collected by 
the study specific case report form (CRF). All the 17 participating ICUs 
belong to the FICC. Data were recorded for the first five days in the ICU. The 
routine FICC’s dataset includes patients basic demographics, data on 
hospital and ICU admission and discharge, APACHE II, III, and 
International Classification of Diseases 10th diagnosis, severity of illness and 
organ dysfunction scores (APACHE II, SAPS II, and SOFA), and outcomes 
(length of stay in ICU and in hospital and ICU and hospital mortality).  
 
In addition to routine dataset, data collection was expanded to record data of 
physiologic values regarding haemodynamics, vasoactive treatments, 
respiratory values, and laboratory values prospectively into the database. 
MAP-values were collected as median values of 2 or 5 minutes in the 
database of participating hospital and manually validated by trained study 
nurses for the first 24 hours in the ICU. The CRF included data of co-
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morbidities, daily medications, health status, known risk factors for AKI, 
laboratory values prior to ICU admission, and daily evaluation of SIRS, 
infection, organ dysfunction, fluid balance, and RRT. Data on CRF were 
collected on the ICU admission and thereafter daily during the first five days 
in the ICU or until ICU discharge. After day five, data on given RRT were 
recorded twice a week. In addition, study physicians or nurses from each of 
the participating ICUs screened patients excluded from the FINNAKI study 
due to chronic dialysis or re-admitted patients who received RRT during the 
previous ICU admission for severe sepsis retrospectively. All data were 
managed anonymously with an individual study number for each patient. 
Patients’ personal identity codes were only used to prevent inclusion of 
multiple admissions and to obtain survival data from the Finnish Population 
Register Centre. 
 
For population-based incidence, the referral population of participating 
hospitals on 31st December 2011 was obtained from Statistics Finland 
(http://www.stat.fi). This referral population was used to calculate the 
population-based incidence of severe sepsis. For the population-based 
incidence of severe sepsis associated AKI the number of adults on chronic 
dialysis (N= 1527, provided by the Finnish Registry for Kidney disease312) 
was subtracted from the referral population.  
 
 
4.4 Definitions 
Acute kidney injury (I-IV) 
 
Kidney Disease: Improving global Outcomes (KDIGO) criteria35 were used in 
all studies (I-IV) to define and stage AKI by changes in serum creatinine and 
hourly urine output. The baseline serum creatinine was the latest value 
within a year preceding the study enrolment excluding a week prior to ICU 
admission. The modification in diet in renal disease (MDRD) equation, 
assuming a glomerular filtration rate (GFR) of 75 ml/min/1.73 m2, was used 
to estimate the baseline creatinine for patients lacking baseline creatinine 
value as recommended by the ADQI Working Group.97 
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Acute and chronic health status (I-IV) 
 
Presence of hypotension within 48 hours preceding ICU admission was 
defined as systolic blood pressure <90 mmHg for 1 hour and resuscitation as 
haemodynamic collapse requiring defibrillation, chest compression, or 
administration of epinephrine. Chronic kidney disease (CKD) was defined as 
functional or structural abnormalities of the kidney, or glomerular filtration 
rate (GFR) < 60ml/min/1.73m2, at least one week prior to ICU admission.35 
Hypovolaemia and the presence of disseminated intravascular coagulation 
(DIC, defined by International Society on Thrombosis and Haemostasis313) 
were screened by an attending physician.  
 
Severe sepsis and septic shock (I-IV) 
 
Severe sepsis and septic shock were screened by the attending physician for 
24 h preceding ICU admission and daily to the fifth day in the ICU by the 
American College of Chest Physicians/Society of Critical Care Medicine 
(ACCP/SCCM) criteria.88  
 
Nosocomial infection (I) 
 
An infection not present or incubating at the time of admission to the 
hospital, manifesting later than 48 hours after hospital admission was 
defined as nosocomial infection.314,315. 
 
Organ failure (OF) (I, III, IV) 
 
Organ specific SOFA points ≥3 indicated organ failure130,316. ∆OF (IV) was 
calculated as difference in number of organ failure on between the third and 
the first day in the ICU.317,318 
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Vasopressor load (II) 
 
Vasopressor load was calculated by the following formula: vasopressor load 
(μg/kg/min) = norepinephrine (μg/kg/min) + dopamine (μg/kg/min/2) + 
epinephrine (μg/kg/min) + phenylephrine (μg/kg/min/10).56,319 
Phenylephrine was not used for any patient during the study.  
 
Low-RRT and High-RRT ICUs (III) 
 
The proportion of RRT was calculated by dividing the number of RRT-
treated patients with septic shock by total number of patients with septic 
shock in an individual participating ICU. The ICUs were divided into two 
groups, low-RRT and high-RRT ICUs, according to the median value of the 
proportion of RRT as a cut-off value.  
 
Early AKI (IV) 
 
AKI was defined as AKI, which was diagnosed within the first 24 hours in the 
ICU. 
 
 
4.5 Outcome measures 
Progression of AKI (II) 
 
Progression of AKI was defined as a new onset of AKI or worsening of AKI by 
at least one KDIGO stage during the first five days in the ICU. 
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Standardized mortality ratio (III, IV)  
 
The performance of the ICU and the developed predictive models were 
evaluated by the standardized mortality ratio (SMR), a ratio of observed 
deaths to predicted deaths. The SAPS II-based SMR (III) was calculated 
according to the original SAPS equation.292 In study IV, the number of 
predicted deaths was calculated by using the developed AKI-specific models.  
Mortality (I-IV) 
 
The patients’ vital status were determined at 90-day and at one-year after 
ICU admission. Death dates of patients were obtained from the Finnish 
Population Register Centre by personal identity codes. The Finnish Intensive 
Care Consortium provided the data on ICU and hospital mortality.  
 
 
4.6 Statistical methods 
 
The data are presented as absolute numbers (percentages) and medians 
(interquartile ranges, IQR). For comparison of two groups, the Mann-
Whitney U-test was used for continuous variables and categorical variables 
were compared with the Chi-square test or the Fisher’s exact test, when the 
number of cases in a sample was less than five. Backward stepwise logistic 
regression analyses (with significance of 0.05 for elimination) were 
performed to analyze associations between variables and outcomes and to 
calculate odds ratios (ORs) for independent predictors for outcome (I-IV). 
Variables with P<0.2 by univariable analyses were entered into the 
multivariable regression analyses (I-III). Discrimination of the model (the 
ability of a model to distinguish patients according to outcome) was 
evaluated by calculating the area under the receiver operating characteristic 
curve (AUC) (I, II, IV). The best cut-off values were assessed by the Youden 
Index method (II). 320,321 The Kaplan Meyer method was used for displaying 
the survival curves for patients experiencing severe sepsis-associated AKI (I). 
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Propensity score (III) 
 
The propensity score of a patient describes the probability to receive the 
putative treatment conditional on the pre-treatment covariates.322 The 
method is used to diminish the treatment selection bias and to adjust for 
differences in the characteristics between patients receiving and not 
receiving the treatment.322,323 In study III, a propensity score for RRT was 
generated by logistic regression analysis.  The following confounders related 
to the study endpoint (90-day mortality) or to the treatment (initiation of 
RRT) were entered: serum creatinine value, urine output on the first day in 
the ICU, age categorised by APACHE age groups65, any co-morbidity, SAPS II 
score without age and renal components, and SOFA score without renal 
points on the first day in the ICU.  
 
Development and validation of the predictive model (IV) 
 
Candidate predictors were selected a priori based on previous studies or 
clinical judgment324-328 and by univariable analyses between one-year 
survivors and non-survivors. Both models included only data available at 
that time point. In concordance with general ICU mortality prediction 
models, unknown or missing data regarding medical history were assumed to 
be normal.65,69,71,329. The missing values of continuous data were imputed 
with median value of the variable. 326,330,331 To describe the course of severity 
of illness ∆OF (difference in number of OF on the third and first day in the 
ICU) was entered in the D3 model. As advocated the continuous variables 
were not categorized or dichotomized.324,332-334 
 
The association of candidate predictors and one-year mortality was analyzed 
by multivariable logistic regression analyses with backwards elimination with 
significance level of P<0.05 for stepwise removal.324-326,333 The performances 
of the models were assessed by discrimination, calibration, and precision. 
Discrimination of the model was assessed by concordance statistic (c-
statistic) using the AUC-value.305,335-337 An AUC-value of 0.5 represents the 
same as tossing a coin, whereas AUC values <0.7, >0.7, >0.8, and >0.9 are 
regarded as poor, acceptable, good, and excellent, respectively.338-340 For 
clinical use, an AUC >0.7 is usually considered to be acceptable.292 
Calibration evaluates the correspondence between estimated probabilities of 
outcome and observed outcome.324 Calibration of the model was assessed by 
the Hosmer-Lemeshow goodness-of fit (GoF) chi-squared test.325,326 The P-
value >0.05 of Hosmer-Lemeshow test indicates good calibration.293 
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Currently the most preferred method for internal validation is 
bootstrapping.324,326 Bootstrapping method repeatedly draws samples with 
replacement from the original cohort.324-326 Those samples are comparable 
but not identical to the original data set. The original model is developed and 
the model’s performance is assessed in each bootstrapping sample resulting 
in a mean AUC-value.  
 
In all studies (I-IV) a P<0.05 was considered significant. The time-adjusted 
MAP (II) was calculated using the NCSS software (Kaysville, UT, USA) and 
the bootstrapping was performed with R version 3.0.3 for Mac (R 
Foundation for Statistical Computing, Vienna, Austria). Otherwise all 
analyses were performed using SPSS Statistics versions 19-21 (IBM; Armonk, 
NY USA). 
 
Missing data 
 
Imputation techniques have been advocated to address missing values.326,333 
These techniques are based on available data on patients to estimate and to 
replace the missing data.330,331 The missing values of continuous data were 
imputed with median value of the variable.326(I, IV) Variables with notable  
(>5%) missing data were not considered as predictors.333 The proportion of 
missing data on predictors ranged from 0 to 2.6% in the admission model 
and from 0 to 6.0% in the D3 model. 
 
 
4.7 Ethical aspects 
The Ethics Committee of the Department of Surgery, Hospital District of 
Helsinki and Uusimaa, approved the FINNAKI study protocol nationwide 
and the use of deferred consent. In addition, the Ethics Committees of each 
hospital district were informed of the FINNAKI study. A written study 
informed consent was obtained from patients or next of kin. The collection of 
data of deceased patients if an informed consent could not be obtained was 
approved by the Finnish National Institute of Health.  
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5. RESULTS 
5.1 Incidence of severe sepsis associated AKI (I) 
Of the 2901 patients included in the FINNAKI study during the 5-month 
study period, 31.6% (918) had severe sepsis. The incidence of AKI among 
ICU-treated patients with severe sepsis was 53.2% (488/918, 95% CI 49.9 -
56.5%). Of the 918 patients with severe sepsis, KDIGO stage 1 AKI was 
present in 21.1% (197), stage 2 10.6% (97), and stage 3 in 21.5% (197). RRT 
was administrated to 15.0% (138/918) during the first five days in the ICU. 
AKI was more common (59.6%, 433/726) in patients with septic shock 
compared to 28.6% (55/192) of patients with severe sepsis (P <0.001). The 
population-based incidence of AKI in ICU-treated patients with severe sepsis 
(95%CI) was 0.32 (0.30-0.34) /1000 adults /year.  
 
Patients with severe sepsis associated AKI were older (66 years vs. 63 years, 
P=0.002) and had a higher BMI (27.4 kg/m2 vs. 25.9 kg/m2, P<0.001) than 
those without AKI. They were more severely ill (higher SAPS II score), 
received vasoactive therapy more often (P<0.001), and were mechanical 
ventilated more often (P=0.004). The proportions of patients with co-
morbidities and points of severity of illness scores are presented in Table 10.  
Number of patients in APACHE II diagnostic groups in patients with severe 
sepsis with or without AKI is presented in Table 11. (unpublished data) 
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Table 10. CO-morbidities and severity of illness between patients with severe 
sepsis stratified by presence of AKI. 
 
 
  
Severe sepsis with AKI 
 (N=488) 
Severe sepsis without 
AKI (N=430) 
P-value 
Co-morbidities    
Atherosclerosis 16.3 (78/480) 12.6 (54/424) 0.14 
Chronic liver failure 5.2 (25/482) 5.2 (22/425) 0.99 
Chronic renal failure 9.9 (48/484)  2.8 (12/429) <0.001 
COPD 11.4 (55/481) 13.1 (56/426) 0.43 
Diabetes mellitus 29.3 (143/488)) 19.8 (85/430) 0.001 
Hypertension 56.2 (272/484) 48.5 (207/427) 0.02 
Immunosuppression 7.2 (35/481) 8.0 (34/426) 0.69 
Systolic heart failure 10.8 (52/481) 10.8 (46) 0.99 
APACHE 1 27.0 ?21.0-33.0? 21.0 ?17.0-26.0? <0.001 
SAPS II  48.0 [38.0 – 61.0] 37.5 [30.0 – 46.0] <0.001 
SOFAmax 11.0 ?9.0-14.0? 8.0 ?6.0-10.0? <0.001 
COPD chronic obstructive pulmonary disease; APACHE Acute Physiology and Chronic Health 
Evaluation SAPS Simplified Acute Physiology Score; SOFA Sequential Organ Failure Assessment 
1 unpublished data 
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Table 11. The number (%) of patients with severe sepsis in APACHE II diagnostic 
groups stratified by presence of AKI (unpublished data) 
APACHE II diagnostic 
group 
Severe sepsis 
associated AKI 
(N=488) 
Severe sepsis 
without AKI 
(N= 430) 
P-value 
Non-operative    
Respiratory 101(20.7) 158 (36.7) <0.001 
Sepsis 94 (19.3) 69 (16.0) 0.2 
Gastrointestinal 50 (10.2) 24 (5.6) 0.01 
Cardiovascular 47 (9.6) 26 (6.0) 0.05 
Renal 26 (5.3) 0 <0.001 
Metabolic 21 (4.3) 14 (3.3) 0.41 
Neurological 15 (3.1) 25 (5.8) 0.42 
Trauma  9 (1.8) 5 (1.2) 0.4 
Postoperative    
Respiratory 11 (2.3) 12 (2.8) 0.6 
Gastrointestinal 74 (15.2) 61 (14.2) 0.68 
Cardiovascular 18 (3.7) 10 (2.3) 0.23 
Renal 5 (1.0) 2 (0.5) 0.46 
Neurological 3 (0.6) 10 (2.3) 0.46 
Trauma 3 (0.6) 4 (0.9) 0.71 
Other/missing 11 (2.3) 10 (2.3)  
APACHE Acute Physiology and Chronic Health Evaluation; AKI acute kidney injury 
 
 
There was no difference in proportions of severe sepsis patients, with or 
without AKI, who received radio contrast dye prior to ICU admission (22.2% 
vs. 22.4%, P=0.946) (unpublished data). A significantly higher proportion of 
patients with severe sepsis-associated AKI (81.6%) received colloids (starch 
or HES), compared to patients with severe sepsis without AKI (68.5%, 
P<0.001) 24 hours prior to ICU admission or during days 1 to 5 in the ICU.  
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The majority of infections were community acquired in both groups of 
patients. Of the 648 blood cultures taken, 192 (29.6%) were positive. Of the 
positive blood cultures, 63% (121) were taken from patients with severe 
sepsis associated AKI. Details of infection between patients with severe 
sepsis with or without AKI is presented in Table 12. 
 
Table 12 Data on infections in patients with severe sepsis stratified by presence of 
AKI 
 Data 
available 
Severe 
sepsis with 
AKI (N=488) 
Data 
available 
Severe sepsis 
without AKI 
(N=430) 
P-value 
Source of infection       
Abdominal 437 131 (30.0)  393 83 (21.4) 0.005 
Genitourinary 437 39 (8.9)  393 19 (4.8) 0.02 
Pulmonary 437 222 (50.8)  393 245 (62.3) 0.001 
Soft tissue 437  47  (10.8)  393 37 (9.4) 0.52 
   393   
Positive blood 
culture  
353 121 (34.3)  302 71 (23.5) 0.003 
Escherichia coli 121 28 (23.1)  71 8 (11.3) 0.04 
  Other gram 
negative bacteria 
121 28 (23.1)  71 18 (25.4) 0.73 
Enterococcus 
(faecium, 
faecalis) 
121 8 (6.6) 71 4 (5.8)  0.79 
Streptococcus 
pneumoniae 
121 17 (14.0) 71 14 (19.7) 0.30 
Staphylococcus 
aureus 
121 9.1 (11) 71 8 (11.3) 0.63 
Other coagulase 
negative 
stafylococci 
121 12 (9.9) 71 6 (8.5)  0.74 
Multiresistant 
bacteria* 
121 2 (1.7) 71 1 (1.4) 0.90 
Yeast 121 5 (4.1) 71 4 (5.6) 0.64 
Other 121 21 (17.4) 71 13 (18.3) 0.87 
*Multriresistant bacteria: methicillin-resistant staphylococcus aureus, vancomycin-resistant 
enterococci; extended spectrum beta lactamase.  
 
  
59 
In addition to 918 patients with severe sepsis, severe sepsis criteria were 
fulfilled in 23.3% (17/72) of the retrospectively screened patients, who were 
initially excluded from the FINNAKI study. Altogether 935 patients had 
severe sepsis during the study period. Using a corresponding 3-month study 
period and the same inclusion and exclusion criteria as in the original 
FINNSEPSIS study3,  the population based incidence of severe sepsis was 
0.60 (95%CI 0.57-0.62)/1000 adults/year vs. 0.39/1000 adults/1000 (95% 
CI 0.37-0.41) in FINNSEPSIS (P<0.001).  
 
 
5.2. Association with early haemodynamics and 
progression of septic AKI (II)  
The development of AKI was present in 36.2% (153/423) of patients with 
severe sepsis within the first five days in the ICU. Patients with development 
of AKI had lower time-adjusted MAP (74mmHg, IQR 68-81mmHg) 
compared to those without progression (79mmHg, IQR 73-85mmHg, 
P<0.001). Except for the highest MAP threshold (85 mmHg), the areas under 
the mean arterial pressure (MAP AUCs) under all other MAP thresholds (55-
80 mmHg) were larger in patients with progression of AKI compared to 
patients without progression of AKI. The best cut-off value for time-adjusted 
MAP for predicting progression of AKI by Youden method was 72.7 mmHg. A 
greater proportion of patients with development of AKI received 
norepinephrine or inotropes (P< 0.001 for both) during the first five days in 
the ICU. The maximum dose of norepinephrine was significantly associated 
with progression of AKI, only in the lowest quintile of time-adjusted MAP 
(47.2 – 69.5 mmHg, P<0.001).  
Both time-adjusted MAP as a continuous covariate (OR 0.96, 95%CI 
0.94-0.99) and time-adjusted MAP below 73mmHg as a binomial variable 
(OR 2.57, 95% CI 1.48-4.46) were independent predictors for development of 
AKI. (II)  
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5.3 Variation in use of RRT in septic shock associated 
AKI (I) 
Of the 726 patients with septic shock, 436 (60.1%) had AKI and 131 patients 
(18.0%) received RRT. The proportion of RRT-treated patients with septic 
shock varied from 3% (2/76) to 16% (4/25) in the low-RRT ICUs and in the 
high-RRT ICUs from 19% (4/21) to 36% (36/99). Except high creatinine, 
indications for and modalities of RRT were similar in both ICU groups. The 
main indications and modalities of RRT are presented in Table 13. The 
median time for initiation of RRT in the high-RRT ICUs were 13.5 hours 
compared to 17.8 hours in low-RRT ICUs (P= 0.9). The SAPS II and SOFA 
scores did not differ between ICU groups, but patients treated in the high-
RRT ICUs more often received organ supportive treatments such as 
mechanical ventilation (P<0.001), sepsis corticosteroid (P<0.001), and 
higher maximum doses of norepinephrine (P<0.001) during the first five 
days in the ICU. No difference in withholding of RRT existed between low- 
and high-RRT ICUs (7.5% vs. 4.5%, P=0.09). Patients with restricted RRT 
were older (69.0 vs. 65.0 years, P=0.009) and were more severely ill (SAPS II 
score 59.5 vs. 44.0, P<0.001) than patients without restrictions in RRT.  
 
Table 13. Main indications and modalities of RRT in high- and low-RRT-ICUs. 
 RRT-treated 
patients in the Low-
RRT ICUs 
RRT-treated 
patients in the High -
RRT ICUs 
P-
value 
Indication of RRT 
Oliguria 29/33 (87.9) 83/98 (84.7) 0.7 
High creatinine 25/33 (75.8) 54/98 (55.1) 0.04 
Acidosis 24/33 (72.7) 72/98 (73.5) 0.9 
Hyperkalemia 9/33 (27.3) 2/98 (20.4) 0.4 
Fluid overload 12/33 (36.4) 43/98 (43.9) 0.4 
Modality of RRT during ICU stay 
Only CRRT 20/33 (60.6) 52/98 (53.1) 0.5 
Only IHD  2/33 (6.1) 11/98 (11.2) 0.4 
CRRT and IHD 11/33 (33.3) 35/98 (35.7) 0.8 
ICU intensive care unit; RRT renal replacement therapy; CRRT continuous renal replacement 
therapy; IHD intermittent haemodialysis  
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5.4 Outcome (I- IV) 
The 90-day mortality of severe sepsis associated AKI increased with severity 
of AKI. The 90-day mortality rates for patients with severe sepsis associated 
AKI, stratified by KDIGO stages and by RRT (I), are shown in Table 13. By 
multivariable regression analysis, comparing to patients with severe sepsis 
without AKI, KDIGO stage 3 AKI, but not less severe AKI, was independently 
associated with 90-day mortality with an OR (95%CI) of 1.937 (1.276-2.940). 
(I)  
 
 
Table 14 90-day mortality rates in patients with severe sepsis stratified by 
presences of AKI and by the severity of AKI (KDIGO stages)35(I) 
 
Patients with severe sepsis (N=918) 90-day mortality 
No-AKI (n=430) 24.7% (106) 
Any AKI (n=488) 38.1% (186) 
Stage 1 ( n=194) 31.4 % (61) 
Stage 2 (n=97) 35.1% (34) 
Stage 3 (n=197) 46.2% (91) 
RRT-patients (n=138) 49.3 
 
 
The 90-day mortality was significantly higher in patients with severe sepsis 
and progression of AKI (32.7%) compared to patients without progression of 
AKI (18.9%, P=0.00) (II).  
 
The mortality of patients with septic shock did not differ between low- and 
high-RRT ICUs (33.9% vs. 36.2%, P=0.5) (III). Likewise, 90-day mortality 
rates were corresponding in RRT-treated patients between low-RRT and 
high-RRT ICUs, 57.6% vs. 49.0% (P= 0.39). Low-RRT or high-RRT ICU or 
RRT were not associated with fatal outcome in multivariable analysis 
adjusted with age, admission type, SAPS II point without age and renal 
components, AKI on the D1 in the ICU, mechanical ventilation, the lowest BE 
value, prior to ICU, the highest norepinephrine dose during the first five days 
in the ICU and with propensity score for RRT. (III)  
 
The mortality in critically ill patients with AKI at 1 year was 39.8%. (IV) 
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5.5 Predictive models for one-year mortality in 
patients with AKI (IV) 
Among patients with AKI, one-year non-survivors were older (P<0.001), and 
more frequently noted chronic comorbidities (higher number of co-
morbidities, P<0.001) and higher acute burden of illness (assesses as higher 
SAPS II, P<0.001) than the survivors. The development cohort for admission 
model comprised all 774 critically ill patients with early AKI and the D3 
model included 399 patients, who stayed in the ICU for at least three days. 
The discrimination of the models improved with longer surveillance time 
from an AUC-value of 0.76 (admission model) to 0.80 (D3 model) in 
detecting patients with a risk for fatal outcome. The mean AUC-values by 
bootstrapping method (an average AUC of 1000 bootstrap samples) 
corresponded with the original models (0.75 for admission model and 0.79 
for D3 model). The independent predictors for one-year mortality in D3 
model were: advanced age, a high number of co-morbidities, poor premorbid 
functional performance, severity of illness, and mechanical ventilation on 
Day 3. Severity of AKI or presence of severe sepsis, were not predictors for 
one-year mortality.  Table 14 shows the results of regression analysis with 
odd rations (OR, 95% CI) of all significant predictors of one-year mortality 
for both models.   
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Table 14. Predictors for one-year mortality in the admission model and D3-model 
for critically ill patients with AKI 
ADMISSION MODEL D3-MODEL  
Predictor OR (95%CI) Predictor OR (95%CI) 
Age, years  1.03 (1.02-1.04) Age, years  1.04 (1.02-1.06) 
Premorbid functional 
performance preceding 
the acute illnessa 
1.75 (1.15-2.68) Modified SAPS II score d 1.03 (1.00-1.05) 
Admission type 
according to SAPS II, 
compared to scheduled 
surgical 
 Number of co-morbidities 1.26 (1.05-1.52) 
 Unscheduled surgical  7.74 (1.65-36.23) Mechanical ventilation on 
the D3  
2.73 (1.62-4.61) 
 Medical  11.30 (2.45-
52.01) 
The lowest BE value on 
D3  
 0.92 (0.87-0.97) 
Arteriosclerosis  1.87 (1.19-2.95) The highest bilirubin 
within D1 to D3 e 
1.02 (1.02-1.03) 
Systolic heart failure  1.83 (1.13-2.95) 
Chronic liver failure 3.79 (1.89-7.43) 
Diabetes mellitus  0.59 (0.41-0.86) 
Malignancy 2.34 (1.43-3.83) 
Hypotension prior to 
ICU admissionb 
1.67 (1.20-2.31) 
Resuscitation prior to 
ICU admissionc 
2.34 (1.42-3.85) 
Admission model: aPremorbid functional performance defined as dependence of assistance in 
premorbid functional performance preceding the acute illness and compared to normal or disable to 
work. bHypotension was defined as systolic blood pressure <90 mmHg for 1 hour, cResuscitation was 
defined as haemodynamic collapse requiring cardiopulmonary resuscitation, defibrillation or 
administration of epinephrine D3 model: dModified SAPS II score SAPS II score without points given 
for age, renal components, bilirubin, and type of admission, eThe proportion of missing values of the 
bilirubin concentration within the first three days was 6.0%. 
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6. DISCUSSION 
6.1. Incidence of severe sepsis and septic shock 
associated AKI 
 
The incidence of ICU-treated severe sepsis associated AKI in this study (53%) 
was in line with results reported previously.9-12,14-16,18,23,140. Depending on the 
definition of AKI, however, and on the severity of sepsis, the incidence of 
sepsis associated AKI have ranged from 13%58 up to 89%. In septic shock, the 
occurrence of AKI has been even more common.12,13,18 In this study, AKI was 
found in 60% of patients with septic shock.  
 
AKI was defined and staged by the KDIGO35 criteria in the present study. The 
current AKI definitions identify patients with AKI somewhat differently. 
AKIN criteria have been shown to identify a few percent more patients with 
sepsis associated AKI and to classify more patients to the worst AKI stage 
compared to RIFLE.9,13,28 In general ICU patients, AKIN criteria have not 
improved the ability to identify patients with AKI100,341 and RIFLE criteria 
have shown better ability to detect patients with AKI.102 The FINNAKI study 
reported identical incidences of ICU-treated AKI defined by KDIGO or by 
AKIN criteria (posthoc).121 These three AKI classifications have also been 
validated in hospitalized patients (medical, surgical, neurological, 
oncological, and psychiatric patients) in Japan the KDIGO and RIFLE 
criteria identified patients with AKI similarly (11%), whereas less than half of 
these patients were defined as patients with AKI with the AKIN criteria.123 
Instead of multiple definitions of AKI, the use of three classifications is 
already an improvement, but to compare results between studies with 
comparable populations, AKI should be defined by one unified classification. 
 
The population-based, ICU-treated, severe sepsis associated AKI incidence 
was 0.34/1000 adults/year. Regrettably, no population based incidence for 
severe sepsis associated AKI has been reported previously. The FINNAKI 
study reported population-based incidence of ICU treated AKI to the value of 
0.75/ 1000 adults/year 121 and two other studies have reported incidences 
varying from 2.15 to 2.90 /1000/year. 131,132 These studies included patients 
from a limited area (Scotland131 and county in U.S132.) rather than 
nationwide, however.  
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During the present study, the population-based incidence of severe sepsis 
was 1.5-fold compared to the incidence reported in the year 2005. A 
corresponding increase in the incidence of sepsis has been reported 
globally,1,5-7,136 despite the fact that the incidence of the most common causes 
of sepsis, such as pneumonia, intra-abdominal infection, and urinary track 
infection, have remained stable or have decreased.342 To avoid bias in the 
comparison of incidence of severe sepsis between the FINNSEPSIS and 
present study: 1) a corresponding 3-month period, 2) the same ICUs, and 3) 
the exactly same inclusion and exclusion criteria were used. One plausible 
explanation for the detected increase in incidence of sepsis is that the 
information and increased knowledge of severe sepsis due to the 
FINNSEPSIS study3 and the recently published international29,90,91 and 
national318,319 severe sepsis guidelines may have promoted better recognition 
of these patients. In addition, all ICU-treated patients, who did not fulfill the 
exclusion criteria, were included in the FINNAKI study and screened for 
severe sepsis and AKI. In the FINNSEPSIS study, ICU-treated patients, who 
filled the criteria for severe sepsis, were included in the FINNSEPSIS study.  
This difference in study enrolment may have increased the number of 
patients with severe sepsis during the FINNAKI study. According to the 
current literature, no other prospective study has compared the changes in 
incidence in ICU-treated severe sepsis in exactly identical ICUs and time 
period, and with the same criteria for severe sepsis.  
 
 
6.2 Mean arterial pressure and progression of AKI  
The hypotensive episodes (MAP below 73 mmHg) during the first 24 hours in 
the ICU were significantly associated with development or worsening of AKI 
in patients with severe sepsis. In close agreement, a MAP level between 72 
and 82 mmHg has been previously suggested to be needed to avoid 
progression of AKI during septic shock57. In addition, MAP levels below 75 
mmHg during the early phase of sepsis have predicted the need for RRT.55,57 
In a large RCT higher MAP-target (80-85 mmHg) during septic shock was 
only beneficial (less RRT) in patients with chronic arterial hypertension.146 
Although recent understanding of pathophysiology in septic AKI has 
elucidated the role of inflammation in development of septic 
AKI,52,54,143,144,176,178 the aetiology of severe sepsis associated AKI is 
multifactorial and hypotensive episodes may predispose patients with sepsis 
to development of AKI. The optimal targeting MAP level is unclear, however , 
the findings of the present study suggest that avoiding MAP levels <73 
mmHg may prevent the development of AKI in patients with severe sepsis. In 
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addition to optimal MAP level, evaluation of renal perfusion pressure is 
essential, especially in the presence of increased intra-abdominal pressure.  
 
Patients with severe sepsis and progression of AKI received higher maximum 
doses of norepinephrine, but the maximum dose of norepinephrine was 
associated with progression of AKI only in the lowest quintile of time-
adjusted MAP. Patients with development of AKI were more severely ill in 
terms of higher lactate concentrations, higher severity of illness score, and 
they received organ supportive treatments more often, and, thus, a plausible 
explanation is that the more severe disturbances in haemodynamics required 
higher doses of norepinephrine. Although norepinephrine has shown to 
increase renal blood flow and urine output and to improve microvascular 
circulation during sepsis39,45,343,344, evidence of adverse outcome due to 
increasing vasopressor load in septic shock has been demonstrated.56 On the 
basis of currently available evidence, restoration of blood pressure with 
administration of norepinephrine is more important than the eventual 
harmful effect of norepinephrine. However, excessive vasopressor load 
should be avoided.  
 
 
6.3 RRT in severe sepsis and septic shock  
Of the patients with severe sepsis, 15% were treated with RRT and of the 
patients with septic shock, 18% received RRT. These proportions are in line 
with reported studies of cases with a corresponding severity of sepsis and 
with the current available definition of AKI (RIFLE, AKIN or KDIGO 
criteria).17,20 In patients with less severe sepsis, the reported proportions of 
RRT-treated patients have been less, <10%.23,58,139 Across participating ICUs, 
10-fold variation (3% to 36%) was found in proportion of RRT-treated 
patients with septic shock. The decision to initiate RRT is based on an 
opinion of the attending physician and on local protocols. A lack of consensus 
guidelines for indications for RRT may partly explain this large variation. 
Patients requiring RRT are severely ill and RRT is a highly complex 
treatment requiring expensive equipment. Therefore, the care of these 
patients may be centralized in some regions or countries. In the present 
study, all participating ICUs had the capacity to provide RRT, but the 
influence of the center policy regarding the initiation of RRT and 
inexperience in RRT can’t be excluded. However, university hospital ICUs 
with proven experience and capacity to provide RRT were equally distributed 
in high- and low-RRT ICUs. In addition, the lowest (3%) and highest 
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proportion (36%) of RRT-treated patients among patients with septic shock 
were both presented in university hospital ICUs. 
 
The most common indications of RRT (oliguria, high creatinine, acidosis, 
hyperkalaemia, and fluid overload) were in line with the B.E.S.T.-study and 
with the practice of European intensivists in low- and high-RRT ICU 
groups.256,257 Apart from emergency indications, initiation of RRT integrates 
multiple aspects of patients’ circumstances, such as progression and severity 
of AKI, pre-existing renal function and other co-morbidities, exposure of 
nephrotoxins, and prognosis of critical illness. Thus, the use of RRT varies 
between patients with corresponding severity of AKI. The treatment with 
RRT predisposes patients to complications related to RRT, such as 
hypotension, electrolyte disturbances, bleeding, punction complications and 
catheter-related infections. A study comparing conservative treatment 
(management of volume and hydration status, and restoration of electrolyte 
and acid- base homeostasis) with RRT found higher mortality in RRT-treated 
patients than in patients receiving conservative treatment.345 Although the 
patients treated with RRT were more severely ill (higher SOFA and APACHE 
II scores) the worse prognosis in RRT-treated patients remained after 
adjustment for severity of illness.345 In the present study, the mortality rates 
between high and low-RRT ICUs did not differ. Neither administration of 
RRT nor group of ICU (low-RRT or high-RRT ICU) were predictive for 
mortality.  
 
In the present study, no differences in use of different modalities of RRT 
(only CRRT, only IHD or both CRRT and IHD) between high-and low-RRT 
ICU existed. European intensivists have been found to prefer CRRT.257 In 
concordance, CRRT was used in 90% of RRT-treated patients with septic 
shock and CRRT was the most common modality in both high- and low-RRT 
ICUs. Patients with septic shock have unstable haemodynamic and IHD has 
been shown to be associated with haemodynamic instability more often than 
CRRT.267,268,271  
 
In line with a previous study,346 treatment restrictions were applied more 
often to RRT-treated patients (45%) compared to only a quarter of patients 
without RRT. Altogether, RRT was restricted in 10% of patients with septic 
shock (III). The proportion of restricted RRT was equal in both ICU groups. 
Congruent to the present results, age, severity of illness, and poor prognosis 
have been reported to associate with treatment restrictions in patients with 
AKI.347 The decision to restrict RRT is difficult and should be based on the 
prognosis of the underlying critical illness and on the expected quality of life 
after intensive care. No differences in age, number of comorbidities, and 
severity of illness scores (non-renal SOFA score on day 1 in the ICU and 
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SAPS II score) existed in patients with restricted initiation of RRT between 
high-and low-RRT ICUs.  
 
6.4 Outcome of severe sepsis associated AKI  
The short-term mortality rates for patients with severe sepsis associated AKI 
were in line with Australian10 and French20 studies, but may be considered 
low compared to other previous studies reporting mortality rates over 40% 
and 75% for patients with septic AKI.11,12,18,25,28 Some of the difference in 
mortality may be explained by differences in severity of sepsis (severe sepsis 
vs. septic shock12,18) and in the definition of AKI (RIFLE,12,18 other definition 
of acute renal failure11,25). A cross-sectional one-day prevalence study from 
Germany has reported 90-day in-hospital mortality of 67% among patients 
with severe sepsis and AKI,11 which is substantially higher than in the present 
study (38%). Patients with severe sepsis associated AKI were more often 
treated with RRT in the German study compared to the present study (42% 
vs. 28%) and they were older (71 years vs. 66 years, respectively), but 
APACHE II score of patients with septic AKI was lower in the German study 
(22 vs. 27). However, AKI was not defined by the current definitions (RIFLE, 
AKIN, or KDIFO) in the German study, and thus, the comparison of patient 
with septic AKI is not eligible.  
The one-year mortality of critically ill patients with AKI (40%) was 
comparable to the mortality rate observed in patients with mild AKI291 but 
lower than in studies reporting one-year mortality for critically ill patients 
with AKI of any severity.74,348 Higher long-term mortality rates have been 
reported in RRT-treated patients.72,78,349,350 These studies have included only 
patients with most severe AKI and thus, they are not directly comparable to 
the present study.  
 
 
6.5 Predictive model for 1-year mortality in patients 
with AKI 
 
In this study, two AKI-specific predictive models for one-year mortality 
among critically ill patients with AKI were developed. Mortality in survivors 
of critical illness after ICU treatment has been reported to remain high 
during the first months after hospital discharge.290 Increased risk for long-
term mortality in AKI survivors has been observed,25,72,73,75-79,139,348 also in 
Finland.78 The mortality rate of patients with AKI has not equalled the 
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average mortality of normal population until one year.351 In addition, one-
year mortality is a relevant patient-centered outcome compared to hospital 
mortality, which is influenced by discharge policy.352 Only one of the AKI-
specific (SHARF II) short-term mortality models has been tested for 
prediction of one-year mortality in the same multicenter cohort as it was 
developed.74.  
 
Most of the previous AKI-specific models are based on data available at a 
single time point. However, patients with progressing AKI have been 
observed to have a worse outcome than patients with stable or improving 
AKI.353 Similarly, worsening of organ function up to four days after the onset 
of sepsis318,354 or three days after initiation of RRT has been found to increase 
the risk of mortality.355 Therefore, in this study two models at two different 
time points were developed (on ICU admission and on the third day in the 
ICU). The longer surveillance period improved the discrimination of the 
model from AUC-value of 0.76 (admission model) to 0.8 (D3 model).  (IV) 
Corresponding improvement in discrimination of the model has also been 
found with the SHARF II model. 82 
 
In concordance with other AKI-specific models, a high number of co-
morbidities, mechanical ventilation, and measurements reflecting organ 
dysfunction (the highest bilirubin value) were also predictors for long-term 
mortality.80-83,86,301 However, contrary to the SHARF II-score82 and 
Chertow’s model301, severe sepsis or AKI did not remain predictors for long-
term mortality in the present models. Most of the AKI-specific models are 
developed on data from the 1990s. The advancements in definition, 
recognition and treatment of severe sepsis and AKI, and the improvement in 
general intensive care5, may have improved the prognosis of these 
syndromes. In addition, due to differences in case-mix and changes in the 
definition of AKI, the previous AKI-specific models may no longer be 
applicable. None of the previous models have used any of the current 
definitions for AKI. This study adds novel predictive models for long-term 
mortality among critically ill patients with AKI. However, external validation 
is essential before the present model can be applied to clinical use.  
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6.6 Strengths and limitations of the studies 
The present study has several strengths. First, the due to the large sample 
size with prospective data collection the results of the study I may be 
considered as generalizable to other populations. The participating ICUs 
covered the majority (85%) of the Finnish adult population121 and 
represented both university and central hospitals. The data were collected 
using automated Internet interfaces and validated in the participating ICUs 
by educated study physicians and nurses. In addition, the study-specific 
additional data collected by CRF was audited in 9 ICUs (randomly chosen) by 
study investigators. Second, AKI was defined using changes in both urine 
output and creatinine, and most importantly, using the most recent KDIGO 
classification. Third, instead of short-term mortality with varying length of 
stay in ICU or hospital a fixed 90-day mortality was used as the endpoint for 
studies I-III and a patient-centered long-term outcome, one- year mortality 
for study IV. The vital status was obtained from the Population Register 
Centre. Fourth, in study 4 the proportion of missing data of only one 
predictor exceeded 5%. (IV) The missing values of continuous data were 
imputated with median value of the variable. (I, IV) As advocated, no 
continuous variable, and only one categorical variable, were dichotomized 
(IV). Internal validation was performed with the bootstrapping method (IV). 
Thus, in summary, the reliability and generalizability of the findings of the 
presented studies are high. 
  
Multiple important limitations in this study need to be discussed, however. 
First, the FINNAKI study design was observational and, thus, able to detect 
only associations with no possibility to prove any causalities (I-IV). Second, 
AKI and severe sepsis were screened only for the first five days in the ICU (I-
IV). The study design may have slightly underestimated the number of 
patients with AKI or severe sepsis. However, the critically ill patients with 
AKI have usually developed the worst AKI stage within the first few days 
(median 2 days) in the ICU.119 In the FINNSEPSIS study, only 2.3% of 
patients with severe sepsis fulfilled the criteria for severe sepsis after the fifth 
day in the ICU. Third, and most importantly, only ICU-treated patients were 
screened (I-IV). A marked proportion of patients with severe sepsis are 
treated on wards.3,356 Likewise a marked number of hospitalized patients 
with AKI are treated in the wards. The majority of these patients have mild 
disease and are treatable on the wards. In some of these patients, treatment 
restriction may have been applied due to severe co-morbidities, such as 
incurable malignancies. However, the aim of this study was to evaluate the 
incidence of ICU-treated severe sepsis associated AKI.  For calculations of 
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incidence of ICU-treated severe sepsis, a part of the patients were screened 
retrospectively, and, thus, few severe sepsis cases may have been missed. In 
addition, the study was accomplished during the autumn and winter seasons, 
which may have influenced the occurrence of severe sepsis due to seasonal 
variation. Fourth, as recommended,97 the MDRD equation was used to 
estimate a baseline Cr for patients lacking the baseline Cr value (I-IV). 
However, none of the current equations is optimal for all patients and causes 
bias.113,115  
 
Study II was an observational study without randomization and 
predetermined targeting MAP levels and, therefore, no firm causal 
conclusion can be drawn about association of MAP level and progression of 
AKI. Second, additional haemodynamic measurements, such as CVP, CO, 
and SVO2 were lacking and the only included parameters to describe the 
hypoperfusion were blood gas values and lactate concentrations. Third, intra-
abdominal pressure (IAP) was measured only in a few (22%) patients with 
suspected high IAP by clinical judgment. Fourth, the exclusion of patients 
who died within the first five days in the ICU may have caused selection bias 
as these patients were most likely the most severely ill. However, these 
patients were excluded to diminish the impact of competing risks between 
progression of AKI and death.  
 
In study III, the sample size was likely inadequate to show possible 
differences between high- and low RRT ICUs. The 10-fold variation in the use 
of RRT across the participating ICUs without influence on mortality calls for 
further evaluation in a larger study. Second, although propensity score323 was 
included to regression analysis, the influence of local experience and practice  
in  initiation of RRT can not be totally adjusted with propensity score.  
 
In study IV, candidate predictors were mainly selected a priori based on 
previous literature and clinical judgment. Therefore, some significant factors 
may have been excluded. Second, although nearly 800 patients with AKI 
were included in the development cohort of the predictive model, a larger 
study population may be required to achieve better performance of the 
model. Third, customization and external validation would certainly improve 
the performance and clinical strength of our model. Fourth, due to a large 
proportion (31%) of missing values in neurologic evaluation in SOFA score 
on the third day in the ICU, it could not be included in the D3 model.  
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6.7 Clinical implications and future perspectives 
AKI often complicates the course of severe sepsis and these patients often 
require organ supportive treatments. Despite advancements in intensive care 
the short- and long-term mortality rates are high in patients with severe 
sepsis. Earlier recognition of sepsis might lead to improved awareness and 
avoidance of additional risk factors related to sepsis and intensive care, such 
as hypotension, hypovolaemia, and administrations of nephrotoxins. This 
may be one of the most important possibilities to prevent the development of 
AKI and associated mortality.   
 
For now, inflammation and overproduction of nitric oxide are suggested to 
play the key role in the development of severe sepsis associated AKI. Until 
better understanding on the precise pathophysiology of severe sepsis 
associated AKI, the haemodynamic circumstances that can predispose 
development of AKI, such as hypotension and hypoperfusion, should be 
avoided. On the other hand, targeting supranormal haemodynamic values 
with excess fluid administration or vasopressor load seem to be harmful. 
Further studies are needed to evaluate the association between different 
targeting MAP levels and especially renal blood flow over time. These studies 
should also take into account the severity of illness and try to standardize 
supportive haemodynamic treatment (fluid balance and vasoactive 
treatment).  
 
The distinct pathophysiology of severe sepsis associated AKI enables 
fascinating possibilities to attempt to diagnose AKI earlier and to develop 
specific treatments for septic AKI. Detecting, removal, and prohibiting the 
inflammatory mediators in early phases of septic AKI could lead to better 
survival of these patients. The prohibition of the inflammatory cascade would 
prevent permanent cell damage and subsequent chronic renal failure 
requiring dialysis. Trials regarding caspase-inhibitors181,357,358 are promising 
but require further investigation. Although the IVOIRE study did not confirm 
the beneficial effect of HVHF (high volume hemofiltration) in severe sepsis, 
theoretically the blood purification with HVHF remains an interesting 
prospect. Perhaps more advanced filters need to be developed to absorb the 
inflammatory mediators. In addition, particularly during HVHF, more 
advanced measurements of therapeutic concentrations of drugs are needed. 
Animal studies with induced sepsis, administration of alkaline phosphatase 
has reduced the inflammatory response and mortality.359,360 Alkaline 
phosphatase is an endogenous enzyme with the ability to reduce 
inflammation by detoxifying endotoxins through dephosphorylation. In 
addition, alkaline phosphatase converts the harmful extracellular adenosine 
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triphosphate into adenosine, which has anti-inflammatory and renal tissue 
protective traits.361,362 The decreased expression of iNO in patients with 
sepsis 363 and improved CrCl in patients with severe sepsis or septic shock 
associated AKI362 have suggested that alkaline phosphatase is a potential new 
treatment option for septic AKI.  In the future, experimental and larger 
clinical trials are warranted for patient selection, timing and dosing of this 
treatment.  
 
In the absence of absolute indications for RRT, the decision to initiate RRT is 
individual for each patient within the context of the patients’ entire clinical 
condition. RRT is a highly invasive and costly treatment. Advantages and 
disadvantages should be considered before administration of RRT to avoid 
exposing patients to unnecessary harm. However, delaying initiation of 
supportive treatment may facilitate more severe organ dysfunction/failures. 
In the future, RCTs are needed to compare equally ill patients randomized to 
different therapeutic approaches and timing of RRT, possibly also including 
conservative treatment for AKI patients. Despite common use of RRT in 
developed countries, the consensus guidelines for indications, timing and 
also withholding of RRT remain lacking.  
 
The objective assessment of an individual patient’s severity of illness and 
prognosis is appealing. Predictive models are important instruments in 
identifying patients with inevitably poor prognosis to avoid futile care. In the 
future, lack of ICU beds may be a more pronounced problem. For now, 
predictive scores provide estimates of the number of patients predicted to 
decease among a group of similar patients. Nevertheless, they do not provide 
predictions of which patients will die. Therefore, decision-making for each 
individual patient treatment should not be solely based on predictive models. 
However, using these instruments to provide additional information in 
decision-making, together with clinical evaluation, is reasonable. A 
combination of several predictive models (for example SAPS II, daily SOFA 
score, and nursing workload) may provide a more accurate estimate of 
prognosis. A large prospective study designed for model developing and 
testing is needed to provide reliable AKI-specific score. Additionally, all new 
models need to be externally validated among patients from different 
geographical regions. 
 
The mortality in hospital survivors of patients with AKI remains increased 
after hospital discharge. Even mild AKI has been shown to increase the risk 
of development of CKD and mortality. Reasonable follow-up, rehabilitation, 
prevention of use of nephrotoxic drugs and earlier diagnosis of possible CKD 
after hospitalization may improve the long-term survival of these patients in 
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the future. Longitudinal register studies of hospital survivors of patients with 
AKI are needed for organization of an optimal follow-up for these patients.  
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7. CONCLUSIONS 
On the basis of the results of the study, the following conclusions are drawn: 
 
1. In the Finnish adult ICUs, the incidence of severe sepsis associated AKI 
was 53%, which was largely consistent with studies using comparable 
definition of AKI. The population-based incidence of ICU-treated patients 
with severe sepsis associated AKI was 0.32/1000 adults/year.  
 
2. The population-based incidence of severe sepsis was 1.5-fold (0.6 vs. 
0.39/1000 adults/ year) compared to the incidence in year 2005.  
 
3. Patients with severe sepsis and progression of AKI had lower time-
adjusted MAP than those without progression. MAP-levels below 73 
mmHg were associated with new onset and development of AKI. 
Progression of AKI was associated with higher mortality than in severe 
sepsis without AKI progression.  
 
4. The proportion of RRT-treated patients in septic shock varied from 3% 
to 36% across Finnish ICUs. Differences in case-mix and severity of organ 
dysfunctions explained the 10-fold variation in the proportion of RRT-
treated patients in low- and high-RRT ICUs. No difference in 90-day 
mortality existed between low and high-RRT ICUs among patient with 
septic shock (34% vs. 36%).  
 
5. Severity of illness, advanced age, poor premorbid functional 
performance, a high number of co-morbidities, and mechanical 
ventilation on Day 3 were independent predictors of one-year mortality, 
but presence of severe sepsis or severity of AKI of was not. The D3-model 
performed fairly well judged by an AUC of 0.8. 
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